Switch to Nicholas Bruchovsky's research page...

1999

1. Bruchovsky N, Klotz LH, Crook JM, Armitage Gr, Hoffart D, Gleave ME, Goldenberg SL. Intermittent endocrine therapy for prostate cancer. In: Schroeder FH, editor. Renal, Bladder and Prostate Cancer: an Update. Parthenon Publishing, Carnforth. p 203-209. (1999).
    Request Paper

1998

2. Bruchovsky N, Goldenberg SL, Gleave ME. Intermittent androgen suppression for the treatment of prostate cancer: In: Belldegrun A, Kirby RS, Oliver T, editors. New Perspectives in Prostate Cancer. Isis Medical Medial Ltd, Oxford. p 273-282. (1998).
    Request Paper

1997

3. Bruchovsky N. Androgens and Anti-androgens. In: Holland JF, Frei III E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer Medicine. 4th. ed. Williams & Wilkins, Baltimore, Maryland. p 1133-1148 (1997).
    Request Paper

4. Gleave ME, Bruchovsky N, Goldenberg SL, Rennie PS. Intermittent androgen suppression: rationale and clinical experience. In: Schroeder F, editor. Recent Advances in Prostate Cancer. The Parthenon Publishing Group Ltd, New York USA, and Carnforrth, UK. p 109-120. (1997).
    Request Paper

5. Goldenberg SL, Bruchovsky N. Androgen withdrawal therapy: new perspectives in the treatment of prostate cancer. In: Raghavan D, Scher HI, Leibel SA, Lange P, editors. Principles and Practice of Genitourinary Oncology. JB Lippincott Company, Philadelphia. 57:583-591. (1997).
    Request Paper

1996

6. Gleave ME, Goldenberg SL, Bruchovsky N. Prostate-specific antigen as a prognostic predictor for prostate cancer. In: Pasqualini JR, Katzenellenbogen BS, editors. Hormone-Dependent Cancer. Marcel Dekker Inc, New York. p425-452 (1996).
    Request Paper

1995

7. Rennie PS, Bruchovsky N, Akakura K, Goldenberg SL, Gleave ME, Sullivan SL. Apoptosis in relation to androgen independence in experimental and clinical prostate cancer. In: Michna H, Tenniswood M, editors. Apoptosis in Hormone Dependent Cancers. Springer-Verlag, Berlin. p 71-82 (1995).
    Request Paper

1994

8. Bruchovsky N, Akakura K, Goldenberg SL, Gleave M, Rennie PS, Sullivan L. Intermittent androgen suppression in the treatment of prostate cancer. In: Imai K, Shimazaki J, Karr JP, editors. Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH. Adenine Press, Schenectady. p 187-197 (1994).
    Request Paper

9. Bruchovsky N, Akakura K, Rennie PS, Goldenberg SL. Adverse effects of androgen ablation on stem cells and clusterin synthesis in the Shionogi carcinoma. In: Imai K, Shimazaki J, Karr JP, editors. Fundamental Approaches to the Diagnosis and Treatment for Prostate Cancer and BPH. Adenine Press, Schenectady. p 103-104 (1994).
    Request Paper

1993

10. Bruchovsky N. Androgens and Anti-androgens. In: Holland JF, Frei III E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer Medicine. 3rd. ed. Lea & Febiger, Philadelphia. p 884-896 (1993).
     Request Paper

1990

11. Bruchovsky N. Preface "Out of sight, out of mind". In: Farnsworth WF, Ablin RJ, editors. The Prostate as an Endocrine Gland. CRC Press, Inc, Boca Raton. (1990).
     Request Paper

1988

12. Bruchovsky N. Hormonal Treatment Approaches to D2 disease. In: Coffey DS, Resnick MI, Dorr FA, Karr JP, editors. A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Alan R Liss Inc, New York. p 245-259 (1988).
     Request Paper

13. Bruchovsky N, Rennie PS, Goldenberg SL. Mechanisms and effects of androgen withdrawal therapies. In: Prostate Cancer: Rationale of Endocrine Management. Walter De Gruyter & Co, Berlin. p 3-14 (1988).
     Request Paper

14. Lawson D, Bruchovsky N, Rennie PS, Goldenberg SL, Fletcher T. Relative effectiveness of androgen withdrawal therapies as measured by changes in the intracellular distributions of androgen receptors and dihydrotestosterone. In: Bresciani F, Lippman ME, King RJB, Raynaud JP, editors. Hormones and Cancer 3, Progress in Cancer Research and Therapy. Vol 35. Raven Press, New York. p 488-495 (1988).
     Request Paper

15. Le Riche JC, Bruchovsky N, Goldenberg SL, de Jong G. Flow cytometry in the cytological and clinical assessment of prostatic carcinoma. In: Karr JP, Coffey DS, Gardner W Jr, editors. Cytopathology/Flow Cytometry and Prognostic Indicators of Prostate Cancer.. Elsevier, New York. p 254-259 (1988).
     Request Paper

1987

16. Bruchovsky N, Brown EM, Coppin CM, Goldenberg SL, Le Riche JC, Murray NC, Rennie PS. The endocrinology and treatment of prostate tumor progression. In: Coffey DS, Bruchovsky N, Gardner WA Jr, Resnick MI, Karr JP, editors. Current Concepts and Approaches to the Study of Prostate Cancer. Alan R Liss Inc, New York. p 347-387 (1987).
     Request Paper

17. Bruchovsky N, Rennie PS, Gout PW, Goldenberg SL. Endocrinology of tumour progression. In: Engelsman E, de Koning Gans HJ, editors. Endocrine-related Tumours. Update-Siebert Publications Ltd, Guildford. p 9-26 (1987).
     Request Paper

18. Coffey DS, Bruchovsky N, Gardner WA Jr, Resnick MI, Karr JP. Current Concepts and Approaches to the Study of Prostate Cancer. In: Coffey DS, Bruchovsky N, Gardner WA Jr, Resnick MI, Karr JP, editors. Alan R Liss Inc, New York. (1987).
     Request Paper

19. Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CML, Brown EM. The use of synergistic hormonal combinations in the treatment of advanced prostatic cancer: cyproterone acetate plus mini-dose diethylstilbestrol. In: Klijn JGM, Paridaens R, Foekens JA, editors. Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti) Steroidal Agents. Raven Press, New York. p 127-133 (1987).
     Request Paper

20. Gout P, Beer CT, De Jong G, Rennie PS, Bruchovsky N. Prolactin-induced generation of transferring receptors: a critical event in the mitogenesis of lactogen-dependent Nb2 node rat lymphoma cells. In: Bresciani F, Lippman ME, King RJB, Raynaud JP, editors. Hormones and Cancer 3, Progress in Cancer Research and Therapy. Vol 35. Raven Press, New York.p 242-249 (1987).
     Request Paper

1986

21. Bruchovsky N. This week’s citation classic. In: Barrett JT, editor. Contemporary Classics in the Life Sciences, Vol 2: The molecules of life. iSi Press, Philadelphia. p 183 (1986).
     Request Paper

1985

22. Bruchovsky N, Chapdelaine A, Neumann F, editors. Regulation of Androgen Action. Congressdruck R. Bruckner, Berlin. (1985).
     Request Paper

23. Bruchovsky N, Dunstan-Adams E. Regulation of 5α-reductase activity in stroma and epithelium of human prostate. In: Bruchovsky N, Chapdelaine A, Neumann F, editors. Regulation of Androgen Action. Congressdruck R Bruckner, Berlin. p 31-35 (1985).
     Request Paper

1984

24. Rennie PS, Bruchovsky N, Cheng H, Foekens JA. Turnover of 3s androgen receptors bound to the nuclear matrix of prostatic nuclei. In: Bresciani F, King RJB, Lippman ME, Namer M, Raynaud JP, editors. Hormones and Cancer 2, Progress in Cancer Research and Therapy. Vol 31. Raven Press, New York. p 73-77 (1984).
     Request Paper

1983

25. Bruchovsky N. Rationale for the use of anti-hormone and drug combinations in the treatment of prostatic carcinoma. In: Schroeder FH, editor. Androgens and Anti-androgens. Schering Nederland BV, Weesp. p 35-51 (1983).
     Request Paper

26. Bruchovsky N, Goldie JH. Basis for the use of drug and hormone combinations in the treatment of endocrine-related cancer. In: Bruchovsky N, Goldie JH, editors. Drug and Hormone Resistance in Neoplasia. Volume II, Clinical Concepts. CRC Press, Boca Raton. (1983).
     Request Paper

27. Goldie JH, Coldman AJ, Bruchovsky N. A quantitative model for drug resistance in cancer chemotherapy. In: Chabner BA, editor. Rationale Basis for Chemotherapy. Alan R Liss Inc, New York. p 23-39 (1983).
     Request Paper

28. McLoughlin MG, Bruchovsky N. Stromal-epithelial interaction. In: Hinmann F Jr, editor. Benign Prostatic Hypertrophy. Springer-Verlag, New York. p 130-140 (1983).
     Request Paper

1982

29. Bruchovsky N, Goldie JH, editors. Drug and Hormone Resistance in Neoplasia. Volume 1, Basic Concepts. RCR Press, Boca Raton. (1982).
     Request Paper

1981

30. Bruchovsky N, McLoughlin MG, Rennie PS, To M. Partial characterization of stromal and epithelial forms of 5α-reductase in human prostate. In: Murphy GP, Sandberg AA, Karr JP, editors. The Prostate Cell: Structure and Function, Part A. Alan R Liss Inc, New York. p 161-175 (1981).
     Request Paper

1980

31. Bruchovsky N. The control of neoplastic growth by alterations in hormonal balance. In: Day SB, Sugarbaker EV, Rosch PJ, Warren BA, editors. Readings in Oncology. International Foundation for Biosocial Development and Human Health, New York. p 37-43 (1980).
     Request Paper

32. Bruchovsky N, Callaway T, Lieskovsky G, Rennie PS. Markers of androgen action in human prostate: potential use in the clinical assessment of prostatic carcinoma. In Wittliff JL, Dapunt O, editors. Steroid Receptors and Hormone-Dependent Neoplasia. Masson Publishing, New York. p 121-131 (1980).
     Request Paper

33. Bruchovsky N, Rennie PS, Shnitka TK. Cellular factors contributing to the high concentration of dihydrotestosterone in hyperplastic and carcinomatous human prostates. In: Iacobelli S, King RJB, Lindner HR, Lippman ME, editors. Hormones and Cancer, Progress in Cancer Research and Therapy. Vol 14. Raven Press, New York. p 457-470 (1980).
     Request Paper

34. Rennie PS, Bruchovsky N. Measurement of androgen receptors. In: Spring-Mills E, Hafez ESE, editors. Male Accessory Sex Glands Human Reproductive Medicine. Vol 4. Elsevier/North-Holland Biomedical Press, Amsterdam. p 265-287 (1980).
     Request Paper

1979

35. Bruchovsky N. Molekulare wirkung von androgenen und antiandrogenen. In: Hamerstein J, Lachnit-Fixon U, Neumann F, Plewig G, editors. Androgenisierungserscheinungen bei der Frau. Excerpta Medica Amsterdam. p 7-21 (1979).
     Request Paper

36. Bruchovsky N, Rennie PS, Wilkin RP. New aspects of androgen action in the prostatic cells: stromal localization of 5α-reductase, nuclear abundance of androstanolone and binding of receptor to linker deoxyribonucleic acid. In: Schroeder FH, de Voogt HJ, editors. Steroid Receptors, Metabolism and Prostatic Cancer. Excerpta Medica Amsterdam. p 57-76 (1979).
     Request Paper

1975

37. Bruchovsky N, Lesser B, Rennie PS. Control of the concentration and distribution of dihydrotestosterone in prostatic cells. In: Goland M, editor. Normal and abnormal growth of the prostate. Charles C Thomas, Springfield. p 125-143 (1975).
     Request Paper

2001

1. Bruchovsky N. Intermittent Androgen Blockade in the Treatment of Prostate Cancer 7th International Congress of Andrology, Montreal, Quebec (2001).
    Request Paper

2. Bruchovsky N. The Ups and Downs of the Hormonal Management of Prostate Cancer Endocrinology Grand Rounds, Southwestern Medical School, Dallas, Texas, USA (2001).
    Request Paper

3. Bruchovsky N. The Ups and Downs of the Hormonal Management of Prostate Cancer Department of Urology, Northwestern University, Chicago, Illinois, USA (2001).
    Request Paper

4. Bruchovsky N, Goldenberg SL, Mawji NR, Sadar MD. Evolving aspects of intermittent androgen blockade for prostate cancer: diagnosis and treatment of early tumor progression and maintenance of remission. Proc 7th Int Congr Androl, (accepted for publication) (2001).
    Request Paper

2000

5. Bruchovsky N. Canadian Prospective Trial of Intermittent Androgen Suppression for Men in Biomedical Relapse After Radiation of Locally Advanced Prostate Cancer Fifth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer, Boston, Massachusetts, USA (2000).
    Request Paper

6. Bruchovsky N. Novel Targets for Cancer Treatment: From Bench to Bedside, Including Case Studies Highlighting Critical Issues in the Management of Hormone Dependent Cancers Hormones and Cancer 2000, Port Douglas, Australia (2000).
    Request Paper

7. Bruchovsky N. The Ups and Downs of Hormonal Therapy for Prostate Cancer Sydney Urological Association, Sydney, Australia (2000).
    Request Paper

8. Bruchovsky N. The Ups and Downs of the Hormonal Management of Prostate Cancer Annual BC Cancer Agency Clinical Cancer Conference, Vancouver, British Columbia (2000).
    Request Paper

9. Bruchovsky N. Intermittent Androgen Deprivation Carcinoma della Prostata, Convegno Internazionale, Genova, Italy (2000).
    Request Paper

10. Bruchovsky N. Intermittent Androgen Suppression for prostate cancer and update A) Prince of Wales Hospital, Sydney; B) Sir Charles Gairdner Hospital, Perth; C) Flinders University and Flinders Medical Centre, Adelaide, Australia (2000).
     Request Paper

11. Bruchovsky N, Theyer G. 2nd International Workshop on Intermittent Androgen Ablation Therapy, Meeting Report. Euro Urol Today 11(3):4-5 (2000).
     Request Paper

1999

12. Bruchovsky N. Intermittent Androgen Suppression for Prostate Cancer, Early Tumour Progression and Therapy With Anti-Sense bcl-2 Oligonucleotides St Bartholomew's Hospital, London, England (1999).
     Request Paper

13. Bruchovsky N. Prostate Cancer: Molecular Biology of Early Progression to Androgen Independence University of Innsbruck, Innsbruck, Austria (1999).
     Request Paper

14. Bruchovsky N. Canadian Prospective Trial on Intermittent Androgen Suppression for Prostate Cancer 2nd International Meeting on Intermittent Androgen Ablation Therapy, Emmersdorf, Austria (1999).
     Request Paper

1998

15. Bruchovsky N. Intermittent Androgen Suppression for Prostate Cancer Patients Failing Radiation Therapy With a Rising PSA: Background and Recent Experience Chemotherapy Foundation Symposium XVI, Innovative Cancer Therapy for Tomorrow, New York, New York, USA (1998).
     Request Paper

16. Bruchovsky N. Intermittent Endocrine Therapy for Prostate Cancer Symposium on Progress and Controversies in Oncological Urology V (PAC10U V): An Update on Renal, Bladder and Prostate Cancer, Rotterdam, The Netherlands (1998).
     Request Paper

1997

17. Bruchovsky N. Intermittent Hormone Blockade in the Treatment of Prostate Cancer Northwest Prostate Cancer Forum, University of Washington, Seattle, Washington, USA (1997).
     Request Paper

18. Bruchovsky N. A) Prostate Cancer: Does Intermittent Androgen Suppression Have a Future? B) Progression to Androgen Independence: A Wealth of New Information from Tumour Models of Prostate Cancer 70th Reunion of the Department of Urology, Dalhousie University, Halifax, Nova Scotia (1997).
     Request Paper

19. Bruchovsky N. AP-1 and the Androgen Receptor: Factors in the Endocrine - Related Progression of Prostate Cancer Gordon Research Conference on Hormonal Carcinogenesis, Tilton, New Hampshire, USA (1997).
     Request Paper

20. Bruchovsky N. Intermittent Endocrine Treatment International Symposium on Developments in Endocrine Management of Prostate Cancer, Berlin, Germany (1997).
     Request Paper

21. Bruchovsky N. The Use of LHRH Agonists in the Treatment of Prostate Cancer Alza Corporation, Palo Alto, California, USA (1997).
     Request Paper

22. Bruchovsky N. Intermittent Endocrine Therapy for Prostate Cancer: An Update Society of Urologic Surgeons of Ontario, Toronto, Ontario (1997).
     Request Paper

23. Bruchovsky N. Basic and Clinical Significance of Antiandrogen Intermittent Suppression (Società Italiana di Andrologia) IV Giornate Andrologiche Italiane, University of Perguria, Perugia, Italy (1997).
     Request Paper

24. Bruchovsky N. Update on Hormonal Treatment of Prostatic Cancer Schools of Specialization in Oncology, Urology, Endocrinology and Surgery, University of Perugia, Perugia, Italy (1997).
     Request Paper

25. Bruchovsky N. Recent Advances in the Treatment of Prostatic Cancer Prostate Cancer Support Group, Salt Spring Island, British Columbia (1997).
     Request Paper

26. Bruchovsky N. Intermittent Androgen Suppression for Prostate Cancer: Recent Progress and Future Directories Bodo von Garrelts lecture, Karolinska Institute, Huddinge, Sweden (1997).
     Request Paper

27. Bruchovsky N. Prostate Cancer: Intermittent Hormone Therapy Ankara, Turkey (1997).
     Request Paper

28. Bruchovsky N. Prostate Cancer: Intermittent Hormone Therapy Antiandrogen Symposium, Izmir, Turkey (1997).
     Request Paper

29. Bruchovsky N. Prostatic Cancer: Intermittent Hormone Therapy Antiandrogen Symposium, Istanbal, Turkey (1997).
     Request Paper

30. Bruchovsky N. Intermittent Androgen Suppression for Prostate Cancer: Recent Progress and Future Directions Hamilton Regional Cancer Center, Hamilton, Ontario (1997).
     Request Paper

31. Bruchovsky N. Intermittent Androgen Suppression: A New Treatment Option for Prostate Cancer Workshop in Prostatic Disease Management, Sunnybrook Medical Center, Toronto, Ontario (1997).
     Request Paper

1996

32. Bruchovsky N. A) Intermittent Androgen Suppression for Prostate Cancer - Rationale and Clinical Experience B) Molecular Biology in Cancer of the Prostate Northern Section of the Urological Society of Australasia, Maroochydore, Queensland, Australia (1996).
     Request Paper

33. Bruchovsky N. Androgenic Regulation of PSA: Molecular, Translational and Clinical Aspects Annual Meeting, Western Australian Section of the Urological Society of Australasia, Bunbury, Western Australia (1996).
     Request Paper

34. Bruchovsky N. Biological Stepping Stones to a New Therapy for Prostate Cancer Symposium on the Biology and Treatment of Prostate Cancer, Toronto Hospital, University of Toronto, Toronto, Ontario (1996).
     Request Paper

35. Bruchovsky N. Intermittent Androgen Suppression for the Treatment of Prostate Cancer Second International Forum on Prostate Cancer, The Prostate Cancer Charitable Trust, London, England (1996).
     Request Paper

36. Bruchovsky N. Intermittent Androgen Suppression for Prostate Cancer: Rationale and Clinical Experience Northwestern University Robert H. Lurie Cancer Center, Chicago, Illinois, USA (1996).
     Request Paper

37. Bruchovsky N. Prostate Cancer - A Time for Optimism Urological Society of Victoria, Melbourne, Victoria, Australia (1996).
     Request Paper

38. Bruchovsky N. Repressor Function of Ap-1/c-Jun in the Androgenic Regulation of the PSA Gene Aniology Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia (1996).
     Request Paper

39. Bruchovsky N. Intermittent Androgen Suppression for the Treatment of Prostate Cancer Sydney, Australia (1996).
     Request Paper

40. Bruchovsky N. Prepressor Function of Ap-1/C-Jun in the Androgenic Regulation of the PSA Gene Flinders University of Southern Australia, Adelaid, South Australia (1996).
     Request Paper

41. Bruchovsky N. A) Neoadjuvant Androgen Withdrawal Therapy Before Radical Prostatectomy: Three Months Versus Eight B) Control of Tumour Progression by Androgens C) Induction of Cell-Free In-vitro Transcription by Recombinant Androgen Receptor Peptides: a Tool for Studying Androgen Receptor Regulation and Tumour Progression D) Androgenic Regulation of PSA: Molecular, Translational and Clinical Aspects Annual Meeting, New South Wales Section of the Urological Society of Australasia, Mt. Broughton, New South Wales, Australia (1996).
     Request Paper

42. Bruchovsky N. Advances in the Treatment of Prostate Cancer: Intermittent Androgen Suppression and Long-Term Neoadjuvant Therapy Urological Society of South Australia, Adelaide, South Australia (1996).
     Request Paper

1995

43. Bruchovsky N. Mechanisms of Prostate Tumor Progression and Maintenance of Androgen Dependence International Conference on Androgenic Hormones, Prostate Cancer and Benign Prostatic Hyperplasia, New Orleans, Louisiana, USA (1995).
     Request Paper

44. Bruchovsky N. Neoadjuvant Hormonal Therapy for Prostate Cancer: The Canadian Experience First International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer, Boston, Massachusetts, USA (1995).
     Request Paper

45. Bruchovsky N. Calreticulin and Clusterin, Two Proteins With Possible Nuclear Functions that are Implicated in the Regulation of the Early and Late Stages of Apoptosis New Orleans, Louisiana, USA (1995).
     Request Paper

46. Bruchovsky N. The 3R's (Reductase, Receptor, Response Element) of Androgen Action: Basis of a Novel Therapy for Prostate Cancer Japanese Urological Association 83rd Annual Meeting, Mukahari, Japan (1995).
     Request Paper

47. Bruchovsky N. Intermittent Androgen Blockade International Conference on Prostatic Carcinoma, Copenhagen, Denmark (1995).
     Request Paper

48. Bruchovsky N. Intermittent Androgen Suppression- the Vancouver Experience Mini-symposium on Intermittent Androgen Suppression, Victoria, British Columbia (1995).
     Request Paper

49. Bruchovsky N. Update on Intermittent Androgen Suppression in the Treatment of Prostate Cancer Urology symposium on "Androgenentzug und Lebensqualität", Vienna, Austria (1995).
     Request Paper

50. Bruchovsky N, Goldenberg SL, Gleave ME, Akakura K, Sato N, Rennie PS. Intermittent androgen blockade. In: Abrahamson PA, Iversen P, editors. Proceedings of the International Conference on Prostatic Carcinoma. Wells Medical Limited, Royal Tunbridge Wells. p 43-47 (1995).
     Request Paper

1994

51. Bruchovsky N. Adaptation and Tumor Progression After Androgen Ablation Society for Basic Urologic Research Fall Symposium, Stanford, California, USA (1994).
     Request Paper

52. Bruchovsky N. Cell Death in the Shionogi Mammary Carcinoma: a Model for Treatment of Hormone Dependent Cancers Tenth International Symposium on Cellular Endocrinology: Molecular and Cell Biology of Apoptosis in Development, Disease and Cancer, W. Alton Jones Cell Science Center, Inc., Lake Placid, New York, USA (1994).
     Request Paper

53. Bruchovsky N. A) Hormonal Rherapy for Prostate Cancer B) Experimental Basis for Intermittent Androgen Suppression of Prostate Cancer Urological Society of Australasia, 47th Annual Scientific Meeting, Broome, Western Australia (1994).
     Request Paper

54. Bruchovsky N. Intermittent Androgen Suppression in the Treatment of Prostate Cancer Institute of Oncology, University of New South Wales, Prince of Wales Hospital, Randwick, New South Wales, Australia (1994).
     Request Paper

55. Bruchovsky N. Prostate Cancer Biology and Novel Therapeutic Strategies Division of Hematology and Oncology Grand Rounds, Wayne State University, Detroit, Michigan, USA (1994).
     Request Paper

56. Bruchovsky N. Novel Approach to Hormonal Therapy for Prostate Cancer Division of Neoplastic Disease Grand Rounds, The Mount Sinai Medical Center, New York, New York, USA (1994).
     Request Paper

57. Bruchovsky N. Biologic and Molecular Aspects of Intermittent Androgen Ablation Samuel Waxman Foundation, Mount Sinai Medical Center, New York, New York, USA (1994).
     Request Paper

58. Bruchovsky N. Intermittent Androgen Suppression in the Treatment of Prostate Cancer Association des Urologues du Québec, XIXe Congrès Annuel, Québec City, Québec (1994).
     Request Paper

59. Bruchovsky N. Biological Basis for Intermittent Androgen Suppression, a Novel Therapy for Prostate Cancer Department of Urology Research Seminar, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA (1994).
     Request Paper

60. Bruchovsky N. Intermittent Androgen Blockade Therapy Chemotherapy Foundation Symposium XII, Innovative Cancer Chemotherapy for Tomorrow, New York, New York, USA (1994).
     Request Paper

61. Bruchovsky N. Nuevas Estrategias de Tratamiento en el Cancer de Prostata XLV Congreso Nacional de Urologia, Cuernavaca, Morelos, Mexico (1994).
     Request Paper

1993

62. Bruchovsky N. Intermittent Hormonal Therapy for Prostate Cancer Satellite Meeting on Urologic Oncology Update, Las Croabas, Puerto Rico (1993).
     Request Paper

63. Bruchovsky N. Prostate Cancer Biology and Novel Therapeutic Strategies Symposium on Expanding Horizons in Prostate Cancer: Advances in the Management of Localized and Disseminated Disease, New York, New York, USA (1993).
     Request Paper

64. Bruchovsky N. Hormone Manipulation: State of the Art Mini-symposium on Prostate Cancer, Kelowna, British Columbia (1993).
     Request Paper

65. Bruchovsky N. A) Mechanisms and Prevention of Tumor Progression B) Protocols for Clinical Trial of Intermittent Androgen Suppression International Workshop on Intermittent Androgen Suppression in Prostate Cancer, Seattle, Washington, USA (1993).
     Request Paper

66. Bruchovsky N. Hormone Manipulation: State of the Art 37th Annual Cancer Symposium: Prostate Cancer, University of Saskatchewan, Saskatoon, Saskatchewan (1993).
     Request Paper

67. Bruchovsky N. Mechanisms of Tumor Progression After Androgen Ablation Adjuvant Therapy of Urological Malignancies. Third Joint Symposium of the University of Vienna and the University of British Columbia, Vienna, Austria (1993).
     Request Paper

68. Bruchovsky N. Biology of Prostate Cell: Role of Hormones University of Chiba, Chiba, Japan (1993).
     Request Paper

69. Bruchovsky N. A) Adverse Effects of Androgen Ablation on Stem Cells and Clusterin Synthesis in the Shionogi Carcinoma B) Intermittent Androgen Suppression in the Treatment of Prostate Cancer The 5th Tokyo Symposium on Prostate Cancer: Fundamental Approach to Diagnosis and Treatment for Prostate Cancer and BPH, Tokyo, Japan (1993).
     Request Paper

70. Bruchovsky N. Biology of the Prostate Cell: Role of Hormones Northeastern Section American Urological Association 45th Annual Meeting, San Juan, Puerto Rico (1993).
     Request Paper

71. Bruchovsky N, Goldenberg SL, Gleave M. Intermittent hormonal therapy for prostate cancer. In: Elhilali M, editor. Urologic Oncology Update, Symposium Proceedings. Stratagem Communications, Don Mills. p 33-37 (1993).
     Request Paper

1992

72. Bruchovsky N. Intermittent Androgen Suppression in the Treatment of Prostatic Carcinoma University of Saskatoon, Saskatoon, Saskatchewan (1992).
     Request Paper

73. Bruchovsky N. Intermittent Androgen Withdrawal Therapy of Prostatic Carcinoma University of Ottawa, Ottawa, Ontario (1992).
     Request Paper

74. Bruchovsky N. A) Intermittent Androgen Withdrawal Therapy for Advanced Prostate Cancer B) Hormonal Therapy: Basic Science Cross Cancer Institute, Edmonton, Alberta (1992).
     Request Paper

75. Bruchovsky N. A) Intermittent Androgen Withdrawal Therapy of Prostate Carcinoma B) Management of Hormone Resistant (Stage D3) Prostatic Carcinoma Second International Prostate Cancer Update, Vail/Beaver Creek, Colorado, USA (1992).
     Request Paper

76. Bruchovsky N. Hormonal Regulation of Prostate Growth Symposium on Modern Trends in Benign Prostatic Hypertrophy Therapy, University of Washington School of Medicine, Seattle, Washington, USA (1992).
     Request Paper

77. Bruchovsky N. A) Biology and Control of Prostate Tumour Progression B) Intermittent Androgen Withdrawal Therapy for Prostate Cancer Toronto-Bayview Regional Cancer Centre, Toronto, Ontario (1992).
     Request Paper

1991

78. Bruchovsky N. Hormone Management of Prostate Cancer The Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA (1991).
     Request Paper

79. Bruchovsky N. Control of Stem Cells in Androgen Dependent Tumors University of Wisconsin Clinical Cancer Center, Madison, Wisconsin, USA (1991).
     Request Paper

80. Bruchovsky N. Maintenance of Apoptotic Potential in Androgen-Dependent Tumors by Intermittent Androgen Withdrawal University of Washington School of Medicine, Seattle, Washington, USA (1991).
     Request Paper

81. Bruchovsky N. Control of Stem Cells in Androgen Dependent Tumors Tufts University School of Medicine, Boston, Massachusetts, USA (1991).
     Request Paper

82. Bruchovsky N. Male Sex Hormones - from A to Z University of British Columbia, Faculty of Medicine, Distinguished Medical Research Lecture, Vancouver, British Columbia (1991).
     Request Paper

83. Bruchovsky N. Regulation of Stem Cells in Androgen Dependent Tumors Terra Symposium on Androgens and Antiandrogens, Mohonk Mountain House, New Paltz, New York, USA (1991).
     Request Paper

1990

84. Bruchovsky N. Benign Prostatic Hyperplasia: Role of Androgens in Etiology - Physiologic and Mechanistic Data Workshop Conference on Androgen Therapy: Biologic and Clinical Consequences, Marco Island, Florida, USA (1990).
     Request Paper

85. Bruchovsky N. New Indications for Antiandrogens in the Treatment of Prostate Cancer Institute for Hormone and Fertility Research, Hamburg, Germany (1990).
     Request Paper

86. Bruchovsky N. Antiandrogens in the Treatment of Advanced Prostate Cancer Division of Urology, University of Viennna, Vienna, Austria (1990).
     Request Paper

1989

87. Bruchovsky N. New Approaches to the Understanding of Hormonal Therapy of Prostatic Cancer Symposium on Urologic Oncology Today & Tomorrow, Toronto, Ontario (1989).
     Request Paper

88. Bruchovsky N. New approaches to the understanding of hormonal therapy of prostatic cancer. In: Trachtenberg J, editor. Urologic Oncology Today & Tomorrow, Symposium Procedings. Stratagem Communications, Don Mills. p 95-101 (1989).
     Request Paper

89. Bruchovsky N, Rennie PS, Goldenberg SL, Coppin CML. Limitations of androgen withdrawal therapy of prostatic carcinoma - the next step? Proc Second Tokyo Symp, Prostatic Carcinoma. Elsevier, New York. p 1-10 (1989).
     Request Paper

1988

90. Bruchovsky N. Mechanism of Action of Androgens and Anti-Androgens Hopital Saint-Francois D'Assise, Québec City, Québec (1988).
     Request Paper

91. Bruchovsky N. The Significance of Stem Cells in the Evolution of Androgen-Independent Malignancy Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado, USA (1988).
     Request Paper

92. Bruchovsky N. Androgenic Action in Prostatic Tissue Symposium on Cell - and Molecular Biology Aspects of Clinical Chemistry zur Verabschiedung von Prof. K. D. Voigt. Universitatskrankenhaus Hamburg- Eppendorf, Federal Republic of Germany (1988).
     Request Paper

93. Bruchovsky N. Limitations of Androgen Withdrawal Therapy of Prostate Cancer - The Next Step? Danish Urologic Society Annual Meeting, Copenhagen, Denmark (1988).
     Request Paper

94. Bruchovsky N. The Significance of Stem Cells in the Evolution of Androgen-Independent Malignancy Department of Medical Nutrition, Karolinska Institute, Stockholm, Sweden (1988).
     Request Paper

95. Bruchovsky N. New Concepts of Androgen Withdrawal Therapies in Prostatic Carcinoma Department of Clinical Urology, Johann-Wolfgang-Goethe-Universitat, Frankfurt,am Main, Federal Republic of Germany (1988).
     Request Paper

96. Bruchovsky N. Second Line Hormone Therapy Symposium - An Update on Prostate Cancer Therapy, Vancouver, British Columbia (1988).
     Request Paper

97. Bruchovsky N. The Significance of Stem Cells in the Evolution of Androgen-Independent Malignancy 8th International Congress of Endocrinology - Satellite Symposium on Sex Steroid-Dependent Tumors, Tokyo, Japan (1988).
     Request Paper

98. Bruchovsky N. Significance of Stem Cells in the Evolution of Androgen Independent Malignancy Lady Davis Institute for Medical Research, Montréal, Québec (1988).
     Request Paper

1987

99. Bruchovsky N. A) Pharmacological Comparison of Available Drugs in the Treatment of Prostatic Cancer B) Hormonal Treatment of Prostatic Cancer: Current Concepts Symposium on Prostatic Cancer: Current Practices and New Therapies, Vancouver, British Columbia (1987).
     Request Paper

100. Bruchovsky N. Pros and Cons of Androgen Withdrawal Therapy B. C. Urological Association Annual Meeting, Vancouver, British Columbia (1987).
      Request Paper

101. Bruchovsky N. Mechanism of Action of Androgens and Anti-Androgens Department of Urology, School of Medicine, Chiba University, Inohana, Chiba-shi, Japan (1987).
      Request Paper

102. Bruchovsky N. Mechanisms and Effects of Androgen Withdrawal Therapies The Third International Congress on Hormones and Cancer Satellite Symposium on Prostate Cancer: Rationale of Endocrine Management, Hamburg, Federal Republic of Germany (1987).
      Request Paper

103. Bruchovsky N. Limitations of Androgen Withdrawal Therapy of Prostatic Carcinoma - The Next Step? The Second Tokyo Symposium on Prostate Cancer, Tokyo, Japan (1987).
      Request Paper

104. Bruchovsky N. Effects of Androgen Withdrawal on the Shionogi Carcinoma Division of Biochemical Pharmacology, Shionogi Research Laboratories, Shionogi & Co. Ltd., Fukushima-ku, Osaka, Japan (1987).
      Request Paper

1986

105. Bruchovsky N. Androgens and Prostatic Carcinoma Katholieke Universiteit Nijmegen, Nijmegen, The Netherlands (1986).
      Request Paper

106. Bruchovsky N. Endocrinology and Treatment of Prostate Tumor Progression Danish Urological Society, Copenhagen, Denmark (1986).
      Request Paper

107. Bruchovsky N. Prostatic Cancer: Recent Advances in Treatment Fourth Oncology Symposium on Vancouver Island, Victoria, British Columbia (1986).
      Request Paper

108. Bruchovsky N. Adverse Effects of Androgen Withdrawal Therapy on the Shionogi Animal Model of Prostatic Carcinoma OSCC Prostate Cancer Program Workshop on A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer, Prouts Neck, Maine, USA (1986).
      Request Paper

109. Bruchovsky N. New Hormonal Therapies of Prostatic Cancer B.C. Society of Medical Oncology, Vancouver, British Columbia (1986).
      Request Paper

110. Bruchovsky N. Treatment and Endocrinology of Prostate Tumor Progression Dr. Daniel Den Hoed Kliniek Rotterdamsch Radio-Therapeutisch Instituut, Rotterdam, The Netherlands (1986).
      Request Paper

1985

111. Bruchovsky N. Rationale for the Use of Cyproterone Acetate and Mini-Dose Diethylstilbestrol in the Treatment of Advanced Prostatic Cancer Symposium on the Molecular Biology of the Prostate and Its Relationship to Prostate Diseases, Canadian Federation of Biological Societies 28th Annual Meeting, Toronto, Ontario (1985).
      Request Paper

112. Bruchovsky N. Antiandrogens and 5a-Reductase Inhibition University of Hamburg, Hamburg, Federal Republic of Germany (1985).
      Request Paper

113. Bruchovsky N. Purification of Nuclear Androgen Receptor and Receptor-Acceptor Complexes Workshop on Methodology of Nuclear Steroid Hormone Receptor Determinations, Noordwijerhout, The Netherlands (1985).
      Request Paper

114. Bruchovsky N. Endocrinology of Tumor Progression Symposium on Endocrine Related Tumours: Facts and Controversies, Noordwijkerhout, The Netherlands (1985).
      Request Paper

115. Bruchovsky N. A) Endocrinology of Tumor Regression: Antiandrogens in Treatment of Prostate Cancer B) Regulation of Androgen Action University of North Carolina, Chapel Hill, USA (1985).
      Request Paper

116. Bruchovsky N. Androgen Metabolism and Antiandrogens in BPH and Prostatic Cancer Sterling-Winthrop Research Institute, Rensselaer, USA (1985).
      Request Paper

117. Bruchovsky N. A) Biologic and Phenotypic Changes During Regression and Recurrence of the Shionogi carcinoma B) Regulation of Androgen Metabolism in the Human Prostate Stanford University, School of Medicine, 13th Annual Symposium on Prostatic Carcinoma, New Frontiers, Palo Alto, USA (1985).
      Request Paper

118. Bruchovsky N. Regulation of Androgen Action in Normal and Abnormal Prostate Terry Fox Course in Basic Sciences of Oncology, Ontario Cancer Institute, Toronto, Ontario (1985).
      Request Paper

119. Bruchovsky N. Synergistic Hormonal Combinations in the Treatment of Prostatic Carcinoma Grand Rounds, Princess Margaret Hospital, Toronto, Ontario (1985).
      Request Paper

120. Bruchovsky N. Tumor Progression and Treatment OSCC Prostate Cancer Program Workshop on Assessment of Current Concepts and Approaches to the Study of Prostatic Cancer, Prouts Neck, Maine, USA (1985).
      Request Paper

1984

121. Bruchovsky N. Androgens, BPH and Prostatic Carcinoma 1984 CSLT National Congress, Vancouver, British Columbia (1984).
      Request Paper

122. Bruchovsky N. Regulation of 5a-Reductase Activity in Stroma and Epithelium of Human Prostate International Symposium on Regulation of Androgen Action, Montreal, Quebec (1984).
      Request Paper

1983

123. Bruchovsky N. Hormonal Mechanisms in the Pathogenesis of Benign Prostatic Hyperplasia Ontario Cancer Institute 25th Anniversary Research Day, Toronto, Ontario (1983).
      Request Paper

124. Bruchovsky N. Carcinoma of the Prostate Canadian Urological Association, 38th Annual Meeting, Victoria, British Columbia (1983).
      Request Paper

125. Bruchovsky N. Mechanisms of Androgen Regulation in Normal and Abnormal Prostate Canadian Investigators in Reproduction, 13th Annual Meeting, Vancouver, British Columbia (1983).
      Request Paper

1982

126. Bruchovsky N. Molecular Action of Cyproterone Acetate Symposium on Pharmacological and Clinical Effects of Cyproterone Acetate Alone or in Combination with Ethinyl Estradiol, Montreal, Quebec (1982).
      Request Paper

127. Bruchovsky N. Stromal and Epithelial Contributions to the Metabolism of Testosterone in the Rat Ventral Prostate and Epididymis Second Meeting of the European Society for Urological Oncology and Endocrinology, Stockholm, Sweden (1982).
      Request Paper

128. Bruchovsky N. Rationale for the Use of Anti-hormone and Drug Combinations in the Treatment of Prostatic Carcinoma International Symposium on Androgens and Anti-Androgens Utrecht, The Netherlands (1982).
      Request Paper

129. Bruchovsky N. Steroid Hormone Receptors in Endocrine-Related Cancer Symposium on Clinical Implications of Receptor Pharmacology, Canadian Society for Clinical Investigation, Quebec, Quebec (1982).
      Request Paper

1981

130. Bruchovsky N. Cell Receptors, Their Role in Managing Endocrine Related Cancers Scientific Advances in Diagnosis and Treatment, Saskatoon, Saskatchewan (1981).
      Request Paper

131. Bruchovsky N. Androgen Metabolism in Stroma and Epithelium of Prostate and Epididymis National Prostatic Cancer Project, Buffalo, New York, USA (1981).
      Request Paper

1980

132. Bruchovsky N. Hormones and Cancer Second Course in Oncology, National Cancer Institute of Canada, Hamilton, Ontario (1980).
      Request Paper

133. Bruchovsky N. Rationale for the Use of Steroid Receptors in the Adjuvant Hormonal Therapy of Breast Cancer Symposium on Management of Early Breast Cancer, Royal College of Physicians and Surgeons, Ottawa, Ontario (1980).
      Request Paper

134. Bruchovsky N. Endocrine Therapy of Prostatic Cancer Advances in Oncology, Vancouver, British Columbia (1980).
      Request Paper

1979

135. Bruchovsky N. Hormone Receptors in Prostatic Tissue Ninth Congress of the International Study Group for Steroid Hormones, Rome, Italy (1979).
      Request Paper

136. Bruchovsky N. Cellular Factors Contributing to the Concentration of Dihydrotestosterone by Hyperplastic and Carcinomatous Human Prostates First International Congress on Hormones and Cancer, Rome, Italy (1979).
      Request Paper

137. Bruchovsky N. Molecular Action of Androgens and Antiandrogens Symposium uber Androgenisierungserscheinungen bei der Frau, Schering AG, Berlin (1979).
      Request Paper

138. Bruchovsky N. Endocrine Therapy and the Theoretical Basic Responses of Neoplasms Institut du Cancer de Montreal, Montreal, Quebec (1979).
      Request Paper

139. Bruchovsky N. Mechanism of Action of Androgens and Antiandrogens Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec (1979).
      Request Paper

140. Bruchovsky N. New Aspects of Androgen Action in the Prostate Lady Davis Institute for Medical Research, Montreal, Quebec (1979).
      Request Paper

141. Bruchovsky N. New Aspects of Androgen Action in the Prostate: Stromal Localization of 5a - Reductase, Nuclear Abundance of Dihydrotestosterone and Binding of Receptor to Linker DNA Workshop of the Society of Urologic Oncology and Endocrinology, Amsterdam, The Netherlands (1979).
      Request Paper

1978

142. Bruchovsky N. A) Estrogen Receptors in Endometrial Carcinoma B) Hormonal Treatment of Endometrial Carcinoma D.A. Boyes Society, Fourth Annual Meeting, Vancouver, British Columbia (1978).
      Request Paper

143. Bruchovsky N. Predictive Markers of Androgen Action in Normal, Hyperplastic and Neoplastic Human Prostates First Innsbruck Winter Conference on Biochemistry in Clinical Medicine, Innsbruck-Igls, Austria (1978).
      Request Paper

144. Bruchovsky N. Markers of Androgen Action in Normal, Hyperplastic and Neoplastic Human Prostates: Clinical Applications Erasmus Universiteit, Rotterdam, The Netherlands (1978).
      Request Paper

145. Bruchovsky N. A) Mechanism of Action of Androgens B) A New Approach to the Hormonal Therapy of Mammary and Prostatic Cancers Katholieke Universiteit, Nijmegen, The Netherlands (1978).
      Request Paper

146. Bruchovsky N. The Control of Prostatic Growth by Alterations in Hormonal Balance Royal Infirmary, Glasgow, United Kingdom (1978).
      Request Paper

147. Bruchovsky N. A) Steroid Receptors and the Regulation of DNA replication B) Considerations in the Hormonal Induction and Regulation of Animal Tumours UICC Prostatic Cancer Workshop, Geneva, Switzerland (1978).
      Request Paper

1977

148. Bruchovsky N. Hormonal Control of Neoplastic Growth Cancer Control Agency of British Columbia, Annual General Meeting, Vancouver, British Columbia (1977).
      Request Paper

149. Bruchovsky N. Steroid Hormones and Tumours of the Male Reproductive Tract Symposium on Hormones and Cancer, Royal College of Physicians and Surgeons, Toronto, Ontario (1977).
      Request Paper

150. Bruchovsky N. Pathological Growth of Androgen Sensitive Tissues Resulting From Latent Actions of Steroid Hormones National Center for Toxicological Research Fourth Annual Hormone Research Symposium, Jefferson, USA (1977).
      Request Paper

1976

151. Bruchovsky N. New Concepts in the Management of Hormone-Sensitive Malignancies National Cancer Institute of Canada, Workshop on Chemotherapy, Winnipeg, Manitoba (1976).
      Request Paper

152. Bruchovsky N. Mechanism of Action of Androgens Johns Hopkins University, Baltimore, USA (1976).
      Request Paper

153. Bruchovsky N. Relationship between Hormone Receptors and Responsiveness of Normal and Neoplastic Cells University of Calgary, Calgary, Alberta (1976).
      Request Paper

154. Bruchovsky N. Relationship between Hormone Receptors and Responsiveness of Normal and Neoplastic Cells University of Western Ontario (1976).
      Request Paper

155. Bruchovsky N. Clinical Studies with Receptors Annual Symposium, Cancer Control Agency of British Columbia, Vancouver, British Columbia (1976).
      Request Paper

1975

156. Bruchovsky N. Hormonal Effects on Cell Proliferation in Rat Prostate International Symposium in Honour of Dr. Charles B. Huggins, Helsingborg, Sweden (1975).
      Request Paper

157. Bruchovsky N. The Effect of Steroid Hormones on Proliferative Growth Symposium on the Control of Differentiated Function in Eukaryotic Cells, Banff, Alberta (1975).
      Request Paper

158. Bruchovsky N. Does 5a-Dihydrotestosterone Cause Benign Prostatic Hyperplasia? Canadian Urological Society, Jasper, Alberta (1975).
      Request Paper

159. Bruchovsky N. Steroid Receptor Proteins and Regulation of Growth in Mammary Carcinoma National Conference on Breast Cancer, Montreal, Quebec (1975).
      Request Paper

160. Bruchovsky N. Receptor Proteins in Tumours Seventh Congress of the International Study Group for Steroid Hormones, Rome, Italy (1975).
      Request Paper

161. Bruchovsky N. Relationship between Hormone Receptors and Responsiveness of Cells Karolinska Institute, Stockholm, Sweden (1975).
      Request Paper

162. Bruchovsky N. Relationship between Hormone Receptors and Responsiveness of Cells Universitats - Krankenhaus Eppendorf, Hamburg, West Germany (1975).
      Request Paper

163. Bruchovsky N. Androgen Receptors in Normal and Neoplastic Tissues Symposium on Hormone Receptors. Canadian Society for Clinical Investigation and the Royal College of Physicians and Surgeons, Winnipeg, Manitoba (1975).
      Request Paper

164. Bruchovsky N. Androgen Receptors in Normal and Neoplastic Cells McGill University, Montreal, Quebec (1975).
      Request Paper

1974

165. Bruchovsky N. The Influence of Androgen Receptors on the Concentration of Androgens in Nuclei of Hormone Responsive Cells Fourth International Congress on Hormonal Steroids, Mexico City, Mexico (1974).
      Request Paper

1973

166. Bruchovsky N. Control of the Concentration and Distribution of Dihydrotestosterone in Prostate Cells International Symposium on Normal and Abnormal Growth of Prostate, San Antonio, Texas, USA (1973).
      Request Paper

2000

1. Akopian V, Bruchovsky N, Beraldi E, Signaevsky M & Sadar MD. Characterization of a new in vivo prostate tumor model 9th Annual Society for Basic Urologic Research (SBUR) Fall Symposium, Fort Meyers, FL, Nov 9-12, 2000:1. (2000).
    Request Paper

2. Gout PW, Buckley AR, Simms CR, & Bruchovsky N. Novel lymphoma growth-inhibitory activity of the immunosuppressant sulfasalazine (SASP), 11th International Congress of Endocrinology (ICE2000), Sydney, Australia, Oct 29-Nov 2 2000:310. (2000).
    Request Paper

3. Kim, Ts-Y, Bruchovsky N, Mcalinden GM, Duncan CP, Edward CJ, Schnabel DD, Schweikert HU & Sadar MD. Androgen-independent activation of the PSA gene by factors secreted from osteoblast-like cells 9th Annual Society for Basic Urologic Research (SBUR) Fall Symposium, P863, Fort Meyers, FL, Nov 9-12, 2000:8. (2000).
    Request Paper

4. Kim, Ts-Y, Fox K, Mawji NR, Hare HA, Schweikert HU, Schnabel DD, McAlinden Gm, Duncan Cp, Jones Ec, Bruchovsky N, & Sadar Md. Androgen-independent activation of the PSA gene by factors secreted from osteoblast-like cells Bridging the Strait of Georgia 5th Symposium on Cancer Research, Victoria, BC, May 31-June 2 (2000).
    Request Paper

5. Mawji NR, Bruchovsky N, Mendelev N, Gout PW & Sadar MD. Androgen-independent increases in prostate-specific antigen gene expression can be inhibited by peptides mimicking sections of the amino-terminus of the androgen receptor Bridging the Strait of Georgia 5th Symposium on Cancer Research, Victoria, BC, May 31-June 2 (2000).
    Request Paper

6. Sadar MD, Bruchovsky N, Gout PW, Snoek R, & Mawji NR,. Androgen-independent increases in the expression of prostate-specific antigen can be inhibited by peptides mimicking sections of the N-terminus of the androgen receptor 11th International Congress of Endocrinology (ICE2000), Sydney, Australia, Oct 29-Nov 2, 2000:310. (2000).
    Request Paper

7. Ueda T, Bruchovsky N & Sadar MD. Activation of the N-terminus domain of the human androgen receptor by interleukin-6 is mediated through MAP kinase and Stat3 signal transduction pathways in prostate cancer cells 9th Annual Society for Basic Urologic Research (SBUR) Fall Symposium, Fort Meyers, FL, Nov 9-12, 2000:22. (2000).
    Request Paper

8. Ueda T, Bruchovsky N, Mawji NR, Hare HA, Snoek R & Sadar MD. Interleukin-6 regulates the prostate-specific antigen gene promoter by activation of the amino-terminal domain of the human androgen receptor 8th SPORE Investigator's Workshop, Rockville, MD, July 9-11, 2000:85. (2000).
    Request Paper

9. Ueda T, Bruchovsky N, Mawji NR, Hare HA, Snoek R & Sadar MD. Interleukin-6 regulates the prostate-specific antigen gene promoter by activation of the amino-terminal domain of the human androgen receptor Bridging the Strait of Georgia 5th Symposium on Cancer Research, Victoria, BC, May 31-June 2 (2000).
    Request Paper

10. Ueda T, Bruchovsky N, Snoek R & Sadar MD. Interleukin-6 regulates the prostate-specific antigen gene promoter by activation of the amino-terminal domain of the human androgen receptor Amer Urol Assoc 95th Annu Mtg Program Abstr J Urol, Atlanta, Georgia, April 29-May 4, 2000:97. (2000).
     Request Paper

11. Ueda T, Bruchovsky N, Snoek R & Sadar MD. Interleukin-6 regulates the prostate-specific antigen gene promoter by activation of the amino-terminal domain of the human androgen receptor 3rd Asian and Oceanic Congress of Andrology, Chiba, Japan, May 24-27 (2000).
     Request Paper

1999

12. Bruchovsky N. Androgen biochemistry 2nd Int Consult Prostate Cancer (1999).
     Request Paper

13. Sadar MD, Bruchovsky N, Mawji N & Gleave M. Ligand-independent activation of the human androgen receptor by butyrate in human prostate cancer cells 7th SPORE Invest Workshop Abstr p. 67. (1999).
     Request Paper

1998

14. Bruchovsky N. Intermittent endocrine therapy for prostate cancer Progr Controversies Oncol Urol V (PACIOU V) An Update on Renal, Bladder and Prostate Cancer Abstr pp. 44-45 (1998).
     Request Paper

15. Bruchovsky N, Klotz LH, Crook JM, Armitage GR, Gleave ME & Goldenberg SL. A phase II study of intermittent androgen suppression (IAS) in men with a rising serum PSA after radiation for localized prostate cancer J Urol 159:335 (1998).
     Request Paper

16. Sadar MD & Bruchovsky N. Increased expression of the prostate specific antigen gene via ligand-independent activation of the androgen receptor 6th SPORE Invest Workshop (1998).
     Request Paper

17. Bruchovsky N. Intermittent androgen suppression for patients failing radiation therapy with a rising PSA: background and recent experience Chemotherap Found Symp XVI Innovative Cancer Therapy for Tomorrow Abstr pp. 58-62 (1998).
     Request Paper

18. Sadar MD, Bruchovsky N & Mawji NR. Increased expression of the prostate specific antigen gene via ligand - independent activation of the androgen receptor Amer Urol Assoc W Sect 74th Annu Mtg Abstr p. 146 (1998).
     Request Paper

1997

19. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N & Sullivan LD. Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy - an update on 125 consecutive patients Can J Urol 4(2):322 (1997).
     Request Paper

20. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N & Sullivan LD. Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy - an update on 125 consecutive patients Br J Urol 80(2):202 (1997).
     Request Paper

21. Goldenberg SL, Bruchovsky N, Gleave ME & Sullivan LD. Failure of radical radiation: Is intermittent androgen suppression an option? Can J Urol 4(2):32 . (1997).
     Request Paper

22. Rennie PS, Goldenberg SL, Bruchovsky N & Gleave ME. Intermittent androgen suppression in the treatment of prostatic carcinoma: an update 5th SPORE Invest Workshop p.11 (1997).
     Request Paper

23. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E & Sullivan LD. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice Br J Urol 80(2):238 (1997).
     Request Paper

24. Snoek R, Bruchovsky N, Sadar MD & Rennie PS. PSA promoter induction of RNA in a cell-free in vitro transcription assay Roy Coll Phys Surg Can Annu Mtg Program Abstr Clin Invest Med 2(4):101 (1997).
     Request Paper

25. Beraldi E, Bruchovsky N, Gleave ME, Goldenberg SL & Rennie PS. Clinical use of nested RT-PCR for PSA during the treatment of prostate cancer by androgen withdrawal therapy Roy Coll Phys Surg Can Annu Mtg Program Abstr Clin Invest Med 2(4):384 (1997).
     Request Paper

26. Bruchovsky N, Klotz L, Crook J, Armitage G, Gleave ME & Goldengerg SL. A phase II study of intermittent androgen suppression in men with a rising serum PSA after radiation for localized prostate cancer Roy Coll Phys Surg Can Annu Mtg Program Abstr Clin Invest Med 2(4):378 (1997).
     Request Paper

27. Gleave ME, Goldenberg SL, Jones E, Bruchovsky N & Sullivan LD. Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy - and update on 125 consecutive patients Amer Urol Assoc 92nd Annu Mtg Program Abstr J Urol 147(4):390 (1997).
     Request Paper

28. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N & Sullivan LD. Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy - an update on 125 consecutive patients W Sect Amer Urol Assoc 73rd Annu Mtg Program Abstr p. 179 (1997).
     Request Paper

29. Goldenberg SL, Bruchovsky N, Gleave ME & Sullivan LD. Intermittent androgen suppression in the treatment of prostatic carcinoma: an update Amer Urol Assoc 92nd Annu Mtg Program Abstr J Urol 147(4):333 (1997).
     Request Paper

30. Goldenberg SL, Bruchovsky N, Gleave ME & Sullivan LD. Intermittent androgen suppression in the treatment of prostatic carcinoma: An update J Urol 157(4):390 (1997).
     Request Paper

31. Goldenberg SL, Bruchovsky N, Gleave ME & Sullivan LD. Intermittent androgen suppression in the treatment of prostatic carcinoma: an update W Sect Amer Urol Assoc 73rd Annu Mtg Program Abstr p. 184 (1997).
     Request Paper

32. Rennie PS, Snoek R, Bruchovsky N, Kasper S, Matusik RJ, Gleave ME, Sato N & Mawji NR. Differential gene induction in prostate cancer cells by AF-1 and AF-2 of the androgen receptor Roy Coll Phys Surg Can Annu Mtg Program Abstr Clin Invest Med 2(4):96 (1997).
     Request Paper

33. Sadar MD, Mawji NR & Bruchovsky N. Androgen-Independent Induction of Prostate Specific Antigen Gen Expression, Via Cross - Talk Between the Androgen Receptor and PKA Signal Transduction Pathways 2nd World Congr Urol Res (1997).
     Request Paper

34. Sadar MD, Sato N, Bruchovsky N, Saaticioglu F, Rennie PS, Sato S, Lange PH & Gleave ME. The role of AP-1 in prostate tumour progression Roy Coll Phys Surg Can Annu Mtg Program Abstr Clin Invest Med 20(4):95 (1997).
     Request Paper

35. Snoek R, Sadar MD, Rennie PS, Nelson C & Bruchovsky N. PSA promoter activity is repressed in PC3 cells compared to LNCaP cells 5th SPORE Invest Workshop (1997).
     Request Paper

1996

36. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N & Sullivan LD. Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy in clinically confined prostate cancer Cancer Invest 14:49-51 (1996).
     Request Paper

37. Gleave ME, Sato N, Goldenberg SL, Bruchovsky N & Sullivan LD. Neoadjuvant androgen ablation reduces local recurrence rates after tumour excision in the androgen-dependent Shionogi tumour model J Urol 155(49):323A (1996).
     Request Paper

38. Gout PW, Kang YJ, Buckley DJ, Bruchovsky N & Buckley AR. Change in thiol growth requirement in the malignant progression of Nb2 lymphoma cells Amer Assoc Cancer Res 87th Annu Mtg Program Abstr p. 37 (1996).
     Request Paper

39. Sadar MD, Bruchovsky N, Akukura K, Rennie PS & Goldenberg SL. Characterization of 5a-reductase gene expression in benign prostate hyperplasia and human prostate cell lines 10th Int Congr Endocrinol Program Abstr (1996).
     Request Paper

40. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL & Sullivan LD. A metastatic and androgen - sensitive human prostate cancer animal model using orthotopic inoculation of LNCaP cells in SCID mic J Urol 155(109):338A (1996).
     Request Paper

1995

41. Bruchovsky N, Akakura K, Rennie PS, Goldenberg SL & Gleave ME. The 3R's (reductase, receptor, response element) of androgen action: basis of a novel therapy for prostate cancer Japanese Urological Association 83rd Annual Meeting Program and Abstracts. Nippon Hinyokika Gakkai Zasshi. Jap J Urol 86(3):348 (1995).
     Request Paper

42. Bruchovsky N, Rennie PS, Goldenberg SL & Gleave ME. Mechanisms of prostatic tumor progression and maintenance of androgen dependence Int Conf Androgenic Hormones, Prostate Cancer Benign Prostatic Hyperplasia, Program Abstr (1995).
     Request Paper

43. Bruchovsky N, Snoek R, Rennie P.S., Dedhar S & Cheng H. Calreticulin and clusterin: two proteins with possible nuclear functions that are implicated in the regulation of the early and late stages of apoptosis Int Conf Androgenic Hormones, Prostate Cancer Benign Prostatic Hyperplasia, Program Abstr (1995).
     Request Paper

44. Cheng H, Rennie PS, Kasper S, Matusik R, Snoek R & Bruchovsky N. Androgen and glucocorticoid receptor interactions with probasin AREs Int Conf Androgenic Hormones, Prostate Cancer Benign Prostatic Hyperplasia, Program Abstr (1995).
     Request Paper

45. Gleave ME, Goldenberg SL, Bruchovsky N, Jones EC & Sullivan LD. Biochemical and pathological effects of eight months of neoadjuvant hormone therapy prior to radical prostatectomy in clinically confined prostate cancer Can J Urol 2(3):A67 (1995).
     Request Paper

46. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N & Sullivan LD. Maximal biochemical and pathological down staging requires 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy J Urol 153(4):392A (1995).
     Request Paper

47. Goldenberg SL, Bruchovsky N, Gleave ME & Sullivan LD,. Intermittent androgen suppression in the treatment of prostate carcinoma Can J Urol 2(3):A67 (1995).
     Request Paper

48. Goldenberg SL, Bruchovsky NB, Gleave ME & Sullivan LD. Intermittent androgen suppression in the treatment of prostate cancer J Urol 153(4):448A (1995).
     Request Paper

49. Sato N, Bruchovsky N, Gleave ME, Rennie PS, Sadar MD & Sato S. Androgenic induction of prostate specific antigen gene is suppressed by direct protein-protein interaction between the androgen receptor and c-Jun or c-Fos in the human prostate cancer cell line LNCaP Amer Urol Assoc 91st Annu Mtg Program Abstr (1995).
     Request Paper

50. Sato N, Gleave ME, Goldenberg SL, Bruchovsky N, Rennie PS & Sullivan LD. Intermittent androgen suppression delays time to androgen-independent progression in the LNCaP prostate tumour model J Urol 153(4):282A (1995).
     Request Paper

51. Sato N, Gleave ME, Rennie PS, Goldenberg SL, Bruchovsky N & Sullivan LD. Intermittent androgen suppression delays progression to androgen-independent state in human prostate cancer, LNCaP tumor model Can J Urol 2(3):A38 (1995).
     Request Paper

52. Sato N, Rennie PS, Goldenberg L, Bruchovsky N & Gleave ME. Intermittent androgen suppression prolongs time to androgen-independent progression in the LNCaP prostate tumor model Int Conf Androgenic Hormones, Prostate Cancer Benign Prostatic Hyperplasia, Program Abstr (1995).
     Request Paper

53. Snoek R, Mawji NR, Rennie PS & Bruchovsky N. Transcriptional modulation by the N-terminal domain of the androgen receptor Int Conf Androgenic Hormones, Prostate Cancer Benign Prostatic Hyperplasia, Program Abstr (1995).
     Request Paper

1994

54. Bruchovsky N, Akakura K & Rennie PS. Experimental basis for intermittent androgen suppression of prostate cancer Urol Soc Australasia 47th Annu Sci Mtg Abstr p. 96 (1994).
     Request Paper

55. Bruchovsky N, Akakura K, Rennie PS & Goldenberg SL. Mechanisms of tumor progression during intermittent androgen suppression J Cell Biochem 18D:Suppl:251 (1994).
     Request Paper

56. Bruchovsky N, Akakura K, Rennie PS, & Snoek R. Structure and function of androgen-receptor in androgen-independent malignancy J Cell Biochem 18B:Suppl:351 (1994).
     Request Paper

57. Bruchovsky N, Akakura K, Rennie PS, Goldenberg SL & Gleave ME. Cell death in the Shionogi mammary carcinoma: a model for treatment of hormone-dependent cancers Tenth Int Symp Cell Endocrinol Program Abstr p. 63 (1994).
     Request Paper

58. Bruchovsky N, Akakura K, Rennie PS, Goldenberg SL & Gleave ME. Adaptation and tumor progression after androgen ablation Soc Basic Urologic Res Fall Symp Program Abstr p. 16 (1994).
     Request Paper

59. Bruchovsky N, Goldenberg SL, Akakura K, Gleave ME & Rennie PS. Hormonal therapy for prostate cancer Urol Soc Australasia 47th Annu Sci Mtg Abstr p. 27 (1994).
     Request Paper

60. Bruchovsky N, Goldenberg SL, Akakura K, Gleave ME & Rennie PS. Intermittent androgen blockade therapy in prostate cancer Cancer Invest 13:Suppl 1:46 (1994).
     Request Paper

61. Gleave ME, Bowden M, Bruchovsky N, Goldenberg SL & Sullivan L. Predictors of time to androgen-independent progression in the LNCaP prostate tumor model J Urol 151: 458A (1994).
     Request Paper

62. Gleave ME, Bruchovsky N, Bowden M, Goldenberg SL & Sullivan LD. Intermittent androgen suppression prolongs time to androgen-independent progression in the LNCaP prostate tumor model J Urol 151: 457A (1994).
     Request Paper

63. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD & Akakura K. Intermittent androgen suppression in the treatment of prostate cancer J Urol 151: 204A (1994).
     Request Paper

64. Gout PW, Fox K, Horsman DE, De Jong G & Bruchovsky N. Cultured rat Nb2 lymphoma cell lines provide a system for in vivo studies of progression of protein hormone-dependent, non-metastatic cancers to hormone independent growth and metastasis Endocrine Soc (U.S.A.) Program Abstr 76th Annu Mtg p. 1026 (1994).
     Request Paper

65. Kasper S, Rennie PS, Bruchovsky N, Sheppard PC, Cheng H, Lin L, Snoek R & Matusik RJ. Androgen specific regulation of the probasin gene is determined by two androgen receptor binding sites and the probasin promoter Endocrine Soc (U.S.A.) Program Abstr 76th Annu Mtg p. 1214 (1994).
     Request Paper

66. Krongrad A, Kasper S., Bai G, Rennie PS, Bruchovsky N & Matusik RJ. Cis-DNA elements bind the androgen receptor and repress expression of the c-fos and ornithine decarboxylase genes Soc Basic Urol Res Annu Mtg Abstr (1994).
     Request Paper

67. Rennie PS, Kasper S, Bruchovsky N, Cheng H, Matusik R & Snoek R. Androgen receptor interactions Soc Basic Urologic Res Fall Symp Program Abstr p. 21 (1994).
     Request Paper

68. Rennie PS, Kasper S, Bruchovsky N, Matusik RJ, Snoek R, Sheppard PC & Cheng H. Two hormone responsive elements, essential for androgen induction of the probasin gene, bind androgen receptors in a cooperative, mutually dependent fashion J Cell Biochem 18B:Suppl:371 (1994).
     Request Paper

69. Sullivan LD, Gleave ME, Goldenberg SL, Bruchovsky N & Jones EC. Long - term neoadjuvant hormone therapy prior to radical prostatectomy in localized prostate cancer J Urol 151: 435A (1994).
     Request Paper

1993

70. Akakura K, Bruchovsky N, Rennie PS, Goldenberg SL & Jones EC. Significance of stromal expression of type 2 5a-reductase mRNA in benign prostatic hyperplasia Soc Basic Urol Res Annu Mtg Abstr (1993).
     Request Paper

71. Akakura K, Bruchovsky N, Rennie PS, Goldenberg SL, Jones EC, Mawji NM & Mawji NR. Significance of stromal expression of type 2 5a-reductase mRNA in benign prostatic hyperplasia Clin Invest Med 16:Suppl:B43 (1993).
     Request Paper

72. Bruchovsky N, Akakura K, Goldenberg SL, Gleave ME, Rennie PS & Sullivan L.D.. Intermittent androgen suppression in the treatment of prostate cancer Int Symp Fundamental Approach Diagnosis Treatment Prostate Cancer BPH Program Abstr p. 35 (1993).
     Request Paper

73. Bruchovsky N, Akakura K, Rennie PS & Goldenberg SL. Adverse effects of androgen ablation on stem cells and clusterin synthesis in the Shionogi carcinoma Int Symp Fundamental Approach Diagnosis Treatment Prostate Cancer BPH Program Abstr p. 17 (1993).
     Request Paper

74. Rennie PS, Bruchovsky N, Snoek R, Sheppard PC, Gustafsson J-A., Dahlman-Wright K & Cheng H. Androgen and glucocorticoid receptors have different binding affinities for two hormonal responsive elements essential for hormonal induction of the probasin gene Endocrine Soc (U.S.A.) Program Abstr 75th Annu Mtg p. 202 (1993).
     Request Paper

75. Sheppard PC, Kasper S, Mcqueen SA, Hoare S, Lin L, Bruchovsky N & Matusik RJ. Preferential androgen action on the prostatic probasin gene requires two androgen receptor binding sites plus adjacent DNA sequences Endocrine Soc (U.S.A.) Program Abstr 75th Annu Mtg p. 203 (1993).
     Request Paper

1992

76. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS & Sullivan LD. Preserved apoptotic potential during intermittent androgen withdrawal therapy in androgen dependent tumors Amer Urol Assoc 87th Annu Mtg Program Abstr p. 453A (1992).
     Request Paper

77. Bruchovsky N, Akakura K, Goldenberg SL & Rennie PS. Preservation of apoptotic potential in androgen-dependent tumors by intermittent androgen withdrawal J Cell Biochem 16D:Suppl:96 (1992).
     Request Paper

78. Goldenberg SL, Bruchovsky N, Akakura K, To M & Rennie PS. PSA response to androgen withdrawal therapy: a predictor of survival W Sect Amer Urol Assoc Program Abstr (1992).
     Request Paper

79. Matusik RJ, McQueen SA, Sheppard PC, Kasper S, Hoare S, Cheng, H, Snoek R, Cattini PA, Bruchovsky N & Rennie PS. Androgen regulation of the prostatic probasin gene requires two cis-acting DNA elements Int Symp Biol Prostate Growth Abstr p. 12 (1992).
     Request Paper

80. Mcqueen SA, Sheppard PC, Hamel A, Cheng H, Snoek R, Bruchovsky N, Rennie PS & Matusik RJ. Characterization of two cis-acting DNA elements responsible for androgen regulation of the prostatic probasin gene Endocrine Soc (USA) Program Abstr 74th Annu Mtg p. 428 (1992).
     Request Paper

81. Rennie PS, Bruchovsky N, Matusik RJ, Gustafsson JA, Dahlman-Wright K & Dedhar S. Interdependent action of glucocorticoid and androgen on the prostate Int Symp Biol Prostate Growth Abstr 30 (1992).
     Request Paper

82. Rennie PS, Bruchovsky N, Snoek R, Cheng H, Sheppard PC, Mcqueen S & Matusik RJ. Two androgen response elements are necessary for androgen regulation of the probasin gene 9th Int Congr Endocrinol Abstr p. 534 (1992).
     Request Paper

83. Snoek R, Rennie PS, Bruchovsky N, Cheng H, Sheppard PC & Matusik RJ. Binding of recombinant androgen receptor peptides to the 5' flanking DNA of the probasin gene Endocrine Soc (USA) Program Abstr 74th Annu Mtg p. 428 (1992).
     Request Paper

1991

84. Akakura K, Otal NK, Rennie PS, Goldenberg SL & Goldenberg N. Effects of intermittent androgen - withdrawal therapy on the growth and progression of androgen-dependent tumours W Sect Amer Urol Assoc Program Abstr p. 63 (1991).
     Request Paper

85. Bruchovsky N, Akakura K, Rennie PS & Goldenberg SL. Regulation of stem cells in androgen-dependent tumors Terra Symp Androgens Antiandrogens Program Abstr p. 22.1 (1991).
     Request Paper

86. Mcqueen SA, Sheppard PC, Cheng H, Bruchovsky N, Rennie PS, Cattini PA & Matusik RJ. Characterization of a DNA element that modulates activity of the androgen responsive element Soc Basic Urol Res Annu Mtg Abstr (1991).
     Request Paper

87. Otal NK, Rennie PS, Bruchovsky N, Goldenberg SL & Tenniswood MPR. Isolation of androgen - repressed genes related to regression of the Shionogi mouse mammary carcinoma Amer Urol Assoc 86th Annu Mtg Program Abstr p. 314A (1991).
     Request Paper

1990

88. Asase D, Katz A, Wise GJ, Olsson CA, Benson MC, Buttyan R, Bruchovsky N, Cheng H & Rennie PS. Potential role for the multiple drug resistance P-glycoprotein in the development of androgen-independent prostate cancer Amer Urol Assoc 85th Annu Mtg Program Abstr p. 204A (1990).
     Request Paper

89. Rennie PS & Bruchovsky N. Activation of cell-death genes in tumorigenic stem cells of androgen-dependent malignancies Second Int Symp Hormonal Manipulation Cancer Program Abstr p. 34 (1990).
     Request Paper

1989

90. Bruchovsky N. New approaches to the understanding of hormonal therapy of prostatic cancer Urol Oncol Today & Tomorrow Abstr Clin Program p. 21 (1989).
     Request Paper

91. Bruchovsky N, Goldenberg SL, Rennie PS & Coppin CML. Pre-suppression of the pituitary: an adjunct to LHRH agonist therapy of prostatic cancer Clin Invest Med 12:R-178 (1989).
     Request Paper

92. Bruchovsky N, Goldenberg SL, Rennie PS, Coldman AJ & Bowden M. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma Clin Invest Med 12:R-179 (1989).
     Request Paper

93. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL & Bowden M. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma Amer Assoc Cancer Res Program Abstr 8th Annu Mtg p. 295 (1989).
     Request Paper

94. Freeman SN, Rennie PS, Bruchovsky N, Cheng H & Tenniswood M. Changes in gene expression in the rat ventral prostate gland following castration and treatment with cortisol Endocrine Soc (U.S.A.) Program Abstr 71st Annu Mtg p. 367 (1989).
     Request Paper

95. Goldenberg SL & Bruchovsky N. Pre-suppression of the pituitary: an adjunct to LHRH agonist therapy of prostate cancer Amer Assoc Cancer Res Program Abstr 8th Annu Mtg p. 309 . (1989).
     Request Paper

1988

96. Bruchovsky N, Rennie PS, Goldenberg SL & Fletcher T. Metabolic significance of stromal 5a-reductase activity in human prostate 8th Int Congr Endocrinol Abstr p. 423 (1988).
     Request Paper

97. Bruchvosky N, Rennie PS & To M. The significance of stem cells in the evolution of androgen - independent malignancy 8th Int Congr Endocrinol - Satellite Symp Sex Steroid-Dependent Tumors Abstr p. 62 (1988).
     Request Paper

98. Buttyan R, Sawczuk I, Benson M, Olsson C, Connor J, Cheng H, Rennie PS & Bruchovsky N. Gene activity during regression of androgen - dependent tissues Proc Amer Assoc Cancer Res 29:239 (1988).
     Request Paper

99. Rennie PS, Bowden JF, Bruchovsky N & Cheng H. Anti-plasminogen activator drugs inhibit the involution of rat ventral prostate 8th Int Congr Endocrinol Abstr p. 414 (1988).
     Request Paper

100. Snoek R, Bruchovsky N & Rennie PS. Purification of a 20,000 dalton protein associated with the nuclear androgen receptor Endocrine Soc (U.S.A.) Program Abstr 70th Annu Mtg p. 93 (1988).
      Request Paper

1987

101. Bowden JF, Rennie PS, Cheng H & Bruchovsky N. Protein components of nuclear androgen receptor acceptor sites in rat ventral prostate Endocrine Soc (U.S.A.) Program Abstr 68th Annu Mtg p. 562. (1987).
      Request Paper

102. Bruchovsky N, Goldenberg SL, Rennie PS, To M & Coppin CML. Mechanisms and effects of androgen withdrawal therapies J Steroid Biochem 28:195S (1987).
      Request Paper

103. Bruchovsky N, Rennie PS, Goldenberg SL & Coppin CML. Limitations of androgen withdrawal therapy of prostatic carcinoma - the next step? Second Symp Prostate Cancer Program Abstr p 9 (1987).
      Request Paper

104. Gout PW, Beer CT, De Jong G, Rennie PS & Bruchovsky N. Prolactin-induced generation of transferring-receptors: a critical event in the mitogenesis of lactogen - dependent Nb2 node rat lymphoma cells J Steroid Biochem 28:141S (1987).
      Request Paper

105. Lawson D, Bruchovsky N, Rennie PS, Goldenberg SL & Fletcher T. Relative effectiveness of androgen withdrawal therapies as measured by changes in the intracellular distributions of androgen receptors and dihydrotestosterone J Steroid Biochem 28:11S (1987).
      Request Paper

106. Rennie PS, Bruchovsky N & Goldenberg SL. Relationship of androgen receptors to the growth and regression of the prostate Eur J Cancer Clin Oncol 23:1248 (1987).
      Request Paper

107. Snoek R, Bruchovsky N & Rennie PS. Protein synthesis in stroma and epithelium of normal, castrated and stimulated rat ventral prostate Endocrine Soc (U.S.A.) Program Abstr 69th Annu Mtg p. 572 (1987).
      Request Paper

1986

108. Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CML & Brown E. Synergistic hormonal combinations in the treatment of advanced prostatic cancer Eur J Cancer Clin Oncol 22:718 (1986).
      Request Paper

1985

109. Bruchovsky N, Goldenberg SL, Coppin E, Brown E & McLoughlin M. Rationale for the use of cyproterone acetate and mini-dose diethylstilbestrol on the treatment of advanced prostatic cancer Proc Can Fed Biol Soc 28:39 (1985).
      Request Paper

110. Bruchovsky N, Goldenberg SL, Crane S, Foekens JA & Rennie PS. Comparative effects of surgical and medical castration on the intracellular distributions of androgen receptors and dihydrotestosterone Clin Invest Med 8:A78 (1985).
      Request Paper

111. Cheng H, Rennie PS, Foekens JA & Bruchovsky N. Covalent cross-linking and purification of androgen receptor-acceptor complexes Clin Invest Med 8:A74 (1985).
      Request Paper

112. Dunstan-Adams, E, Bruchovsky N, Rennie PS, Goldenberg SL & McLoughlin MG. Regulation of dihydrotestosterone in human prostate by 5a-reductase and its inhibitors Clin Invest Med 8:A81 (1985).
      Request Paper

113. Goldenberg SL & Bruchovsky N. Comparative effects of surgical and medical castration on the intracellular distributions of androgen receptor and dihydrotestosterone NW Urol Soc 32nd Annu Mtg Vancouver (1985).
      Request Paper

114. Goldenberg SL, Bruchovsky N, Rennie PS & McLoughlin MG. Protein electrophoretic profiles of prostatic stroma J Urol 133:20 (1985).
      Request Paper

115. Goldenberg SL, Coppin CML, Bruchovsky N & McLoughlin MG. Cyproterone acetate plus mini-dose diethylstilbestrol: initial hormone therapy for advanced prostatic cancer J Urol 133:157 (1985).
      Request Paper

116. Goldenberg SL, Coppin CML, Bruchovsky N, Brown E, Rennie PS & McLoughlin MG. Cyproterone acetate plus mini - dose diethylstilbestrol: initial hormone therapy for advanced prostatic cancer Clin Invest Med 8:A164 (1985).
      Request Paper

117. Goldenberg SL, Coppin CML, Bruchovsky N, Brown E, Rennie PS & McLoughlin MG. Cyproterone acetate plus mini - dose diethylstilbestrol: initial hormone therapy for advanced prostatic cancer NW Urol Soc 32nd Annu Mtg Vancouver . Awarded first prize for best scientific presentation. (1985).
      Request Paper

118. Goldenberg SL, Crane S, Foekens J, Bruchovsky N & Rennie PS. The intracellular distributions of androgen receptor and dihydrotestosterone: a comparison between orchiectomy and antiandrogens J Urol 133:39 (1985).
      Request Paper

119. Gout PW, Bruchovsky N, Rennie PS & Beer CT. The resumption of growth of prolactin - independent Nb rat lymphoma cell cultures, which have been inhibited by sodium butyrate, is markedly stimulated by prolactin Endocrine Soc (U.S.A.) Program Abstr 67th Annu Mtg p. 43 (1985).
      Request Paper

120. Gout PW, Bruchovsky N, Rennie PS & Beer CT. Prolactin markedly accelerates the recovery of butyrate - arrested cells of an autonomous Nb rat lymphoma subline Clin Invest Med 8:A161 (1985).
      Request Paper

121. Otal N, Bruchovsky N, Rennie PS & Giles MG. Expression of androgen related phenotypes during regression and recurrence of the Shionogi mammary carcinoma Clin Invest Med 8:A161 (1985).
      Request Paper

122. Rennie PS, Foekens JA, Cheng H & Bruchovsky N. Androgen interactions with the nuclear matrix and chromatin of the rat prostate Proc Can Fed Biol Soc 28:37 (1985).
      Request Paper

1984

123. Cheng H, Rennie PS & Bruchovsky N. The relationship of plasminogen activators to prostatic involution The Prostate 5:368 (1984).
      Request Paper

124. Crane S, Foekens J, Goldenberg SL, Bruchovsky N & Rennie PS. The intracellular distributions of androgen receptor and dihydrotestosterone: A comparison between orchiectomy and anti-androgens The Prostate 5:338 (1984).
      Request Paper

125. Dunstan-Adams E, Bruchovsky N, Rennie PS, Goldenberg SL & McLoughlin M. Kinetic parameters of 5a-reductase activity and inhibition in stroma and epithelium of human prostate The Prostate 5:332 (1984).
      Request Paper

126. Foekens JA, Rennie PS & Bruchovsky N. Nuclear retention of dihydrotestosterone by non-receptor binding sites The Prostate 5:364 (1984).
      Request Paper

127. Foekens JA, Rennie PS, Cheng H & Bruchovsky N. Effects of micrococcal nuclease and trypsin on the release of androgen receptors covalently bound to the chromatin of rat prostates 7th Int Congr Endocrinol Abstr p. 617 (1984).
      Request Paper

128. Giles MG, Bruchovsky N & Rennie PS. The effects of androgens on the endogenous endonuclease in nuclei isolated from the Shionogi carcinoma The Prostate 5:367 (1984).
      Request Paper

129. Goldenberg SL, Coppin CML, Bruchovsky N, Brown E & McLoughlin M. Cyproterone acetate plus mini-dose diethylstilbestrol: initial hormone therapy for advanced prostatic cancer The Prostate 5:342 (1984).
      Request Paper

130. Goldenberg SL, Giles MG, Bruchovsky N & Rennie PS. Protein electrophoretic profiles of prostatic stroma and epithelium The Prostate 5:336 (1984).
      Request Paper

131. Otal N, Bruchovsky N, Rennie PS & Giles MG. Expression of androgen-related phenotypes during regression recurrent of the shionogi mammary carcinoma The Prostate 5:357 (1984).
      Request Paper

132. To M, Bruchovsky N, Rennie PS & Lefebvre Y. Isolation of chemically demonstrable quantities of nuclear androgen receptor The Prostate 5:359 (1984).
      Request Paper

133. To M, Bruchovsky N, Rennie PS & Lefebvre Y. Isolation of chemically demonstrable quantities of nuclear androgen receptor 7th Int Congr Endocrinol Abstr p. 1618 (1984).
      Request Paper

1983

134. Giles MG, Bruchovsky N & Rennie PS. Androgen regulated gene expression in Shionogi carcinoma Endocrine Soc Program Abstr 65th Annu Mtg p. 122 (1983).
      Request Paper

135. Gout PW, Prior JC, Rennie PS & Bruchovsky N. Multiple forms of serum prolactin in hyperprolactinemia as shown by bioassay: effects of treatment of bromocryptine J Steroid Biochem 19:Suppl:139S (1983).
      Request Paper

136. Rennie PS, Bruchovsky N & Cheng H. Extraction of 3s androgen-receptors from salt resistant fractions and nuclear matrices of prostatic nuclei Endocrine Soc Program Abstr 65th Annu Mtg p. 136 (1983).
      Request Paper

137. Rennie PS, Bruchovsky N, Cheng H And Foekens JA. Turnover of 3s androgen receptors bound to the nuclear matrix of prostatic nuclei J Steroid Biochem 19:Suppl:130S (1983).
      Request Paper

1982

138. Rennie PS, De Larminat MA & Bruchovsky N. The relationship of nuclear concentrations of dihydrotestosterone to androgen-receptors and androgen-mediated responses Endocrine Soc Programr Abstr 64th Annu Mtg p. 351 (1982).
      Request Paper

1981

139. Emerman JT, Leahy M, Gout PW & Bruchovsky N. A possible role for growth hormone in human breast cancer Clin Invest Med 24B (1981).
      Request Paper

140. Leahy M, Emerman JT, Bruchovsky N, Tze WJ, Noble RL, Beer CT & Gout PW. Mitogenic activity of lactogenic hormones in sera from adults and children Clin Invest Med 15B (1981).
      Request Paper

141. Rennie PS, Bruchovsky N & De Jong G. Plasminogen activator is activated in carcinoma of the human prostate and associated with decreased androgen-receptor levels Endocrine Soc Program Abstr 63rd Annu Mtg p. 369 (1981).
      Request Paper

142. Rennie PS, Bruchovsky N & Filipenko JD. Androgenic regulation of superhelical DNA nicking - closing enzyme in rat ventral prostate Clin Invest Med 15B (1981).
      Request Paper

1980

143. De Larminat MA, Bruchovsky N, Rennie PS & Tertzakian G. Use of affinity chromatography for the purification of nuclear androgen-receptors Clin Res 28:670A (1980).
      Request Paper

1979

144. Callaway TW, Bruchovsky N, Rennie PS & Comeau T. Regulation of nuclear abundance of dihydrotestosterone (DHT): evidence for non-receptor mediated processes XI Int Congr Biochem Abstr Short Commun p. 614 (1979).
      Request Paper

145. Rennie PS, Bruchovsky N & Mo S. Elevated levels of plasminogen activator in prostatic tumors of Nb rats Cancer Treat Rep 63:1211 (1979).
      Request Paper

1978

146. Callaway T, Bruchovsky N & Rennie PS. Effects of anti-androgenic compounds on translocation of prostatic androgen receptor Endocrine Soc (U.S.A.) Program Abstr 60th Annu Mtg p. 298 (1978).
      Request Paper

147. Van Doorn EJ & Bruchovsky N. Nuclear binding of 3H-estradiol in human breast cancer Ann Roy Coll Phys Surgs Can 11:89 (1978).
      Request Paper

1977

148. Rennie PS, Bruchovsky N & Noble RL. Acid phosphatase activity and nuclear binding of androgens in prostatic tumours of Noble rats Clin Res 25:710A (1977).
      Request Paper

149. Rennie PS, Koat A & Bruchovsky N. Androgenic regulation of acid phosphatase activity of rat ventral prostate Endocrine Soc (U.S.A.) Program Abstr 59th Annu Mtg p. 85 (1977).
      Request Paper

150. Van Doorn EJ & Bruchovsky N. Mechanisms of replenishment of nuclear androgen receptor in the rat ventral prostate Clin Res 25:685A (1977).
      Request Paper

1976

151. Bruchovsky N. Asymmetry of androgen metabolism in benign prostatic hyperplasia V Int Congr Endocrinol Abstr Short Commun p. 186 (1976).
      Request Paper

152. Bruchovsky N. Asymmetry of androgen metabolism in benign prostatic hyperplasia Ann Roy Coll Phys Surg Can 9:29 (1976).
      Request Paper

153. Koat A, Craven S & Bruchovsky N. A mechanism of control of cytoplasmic androgen receptor concentration V Int Congr Endocrinol Abstr Short Commun p. 15 (1976).
      Request Paper

154. Lieskovsky GJ & Bruchovsky N. Quantitation of androgen receptors in human prostate Ann Roy Coll Phys Surg Can 10:46 (1976).
      Request Paper

155. Rennie PS, Van Doorn E & Bruchovsky N. Analysis of cytoplasmic and nuclear forms of androgen receptors Clin Res 24:662A (1976).
      Request Paper

156. Van Doorn EJ & Bruchovsky N. Synthesis of nuclear androgen receptor in prostatic cells in vivo V Int Congr Endocrinol Abstr Short Commun p. 148 (1976).
      Request Paper

157. Watson GK, Morgan AR & Bruchovsky N. Androgen regulation of superhelical DNA untwisting enzyme V Int Congr Endocrinol Abstr Short Commun p. 14 (1976).
      Request Paper

1975

158. Van Doorn EJ & Bruchovsky N. Synthesis of nuclear androgen receptor Clin Res 23:619A (1975).
      Request Paper

1974

159. Craven S & Bruchovsky N. Transfer of androgens into nuclei of prostatic cells in the absence of cytoplasmic receptors Clin Res 22:730 (1974).
      Request Paper

160. Lesser B, Craven S & Bruchovsky N. Androgen-stimulated growth of rat prostate is independent of cyclic AMP Proc Can Fed Biol Soc 17:625 (1974).
      Request Paper

1973

161. Bruchovsky N & Rennie PS. Transport of androgens in prostatic cells Clin Res 21:1023 (1973).
      Request Paper

162. Bruchovsky N & Sutherland DJ. The incorporation of androgens into nuclei of dependent and autonomous mammary tumour cells Clin Res 21:1066 (1973).
      Request Paper

163. Lesser B & Bruchovsky N. Cell proliferation kinetics in androgen-stimulated rat prostate Proc Can Fed Biol Soc 16:196 (1973).
      Request Paper

164. Rennie PS & Bruchovsky N. Androgen binding proteins of the rat prostate Proc Can Fed Biol Soc 16:8 (1973).
      Request Paper

1972

165. Bruchovsky N & Meakin JW. Androgen uptake and binding by mammary tumours Clin Res 20:947 (1972).
      Request Paper

166. Lesser B & Bruchovsky N. Regulation of prostatic growth by androgens Proc Can Fed Biol Soc 15:413 (1972).
      Request Paper

167. Lesser B & Bruchovsky N. Androgenic regulation of prostatic growth and function Clin Res 20:921 (1972).
      Request Paper

168. Rennie PS & Bruchovsky N. Effect of binding protein on androgen localization in target tissues IV Int Congr Endocrinol Abstr Short Commun p. 79 (1972).
      Request Paper

169. Rennie PS & Bruchovsky N. Androgen uptake by prostatic nuclei Clin Res 20:923 (1972).
      Request Paper

170. Rennie PS & Bruchovsky N. Turnover of protein bound androgens Proc Can Fed Biol Soc 15:412 (1972).
      Request Paper

1971

171. Brown J & Bruchovsky N. A mechanism of androgen control demonstrated in human skin Clin Res 19:770 (1971).
      Request Paper

172. Bruchovsky N. Dihydrotestosterone - A common factor in the action of androgens Clin Res 19:368 (1971).
      Request Paper

173. Bruchovsky N. Cell division induced by 5a-dihydrotestosterone Clin Res 19:770 (1971).
      Request Paper

174. Rennie PS & Bruchovsky N. Comparison of the intracellular binding of testosterone and dihydrotestosterone Proc Can Fed Soc 14:237 (1971).
      Request Paper

1970

175. Bruchovsky N. Factors that regulate the action of testosterone, dihydrotestosterone and androstandiol in rat prostate Clin Res 18:718 (1970).
      Request Paper

1968

176. Bruchovsky N & Wilson JD. The mechanism of action of testosterone in rat prostate J Clin Invest 47:12a (1968).
      Request Paper

177. Bruchovsky N & Wilson JD. Evidence that dihydrotestosterone is the active form of testosterone Clin Res 16:74 (1968).
      Request Paper

2000

1. Bruchovsky N, Klotz LH, Sadar M, Crook JM, Hoffart D, Godwin L, Warkentin M, Gleave ME, Goldenberg SL. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol Urol 4(3):191-9;discussion 201. (2000).
    [View Abstract - PubMed 11062374]  Request Paper

2. Tunn UW, Bruchovsky N, Renneberg H, Wolff JM, Kurek R. Intermittent androgen deprivation Urologe A 39(1):9-13. (2000).
    [View Abstract - PubMed 10663190]  Request Paper

1999

3. Gleave ME, Bruchovsky N, Moore MJ, Venner P. Prostate cancer: 9. Treatment of advanced disease. CMAJ 160(2):225-32. (1999).
    [View Abstract - PubMed 9951446]  Request Paper

4. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 6(4):487-502. (1999).
    [View Abstract - PubMed 10730903]  Request Paper

1998

5. Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Eur Urol 34 Suppl 3:37-41. (1998).
    [View Abstract - PubMed 9854195]  Request Paper

1997

6. Goldenberg SL, Gleave ME, Bruchovsky N, Rennie P. Re: Editorial comment. J Urol 157(6):2267. (1997).
    [View Abstract - PubMed 9146650]  Request Paper

1996

7. Bruchovsky N, Snoek R, Rennie PS, Akakura K, Goldenberg LS, Gleave M. Control of tumor progression by maintenance of apoptosis. Prostate Suppl 6:13-21. (1996).
    [View Abstract - PubMed 8630223]  Request Paper

8. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Semin Urol Oncol 14(2 Suppl 2):39-45; discussion 46-7. (1996).
    [View Abstract - PubMed 8725890]  Request Paper

1995

9. Bruchovsky N, Goldenberg SL, Rennie PS, Gleave M. Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma Urologe A 34(5):389-92. (1995).
    [View Abstract - PubMed 7483155]  Request Paper

10. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45(5):839-44; discussion 844-5. (1995).
     [View Abstract - PubMed 7538246]  Request Paper

1991

11. Goldenberg SL, Bruchovsky N. Use of cyproterone acetate in prostate cancer. Urol Clin North Am 18(1):111-22. (1991).
     [View Abstract - PubMed 1825143]  Request Paper

1988

12. Rennie PS, Bruchovsky N, Goldenberg SL. Relationship of androgen receptors to the growth and regression of the prostate. Am J Clin Oncol 11 Suppl 2:S13-7. (1988).
     [View Abstract - PubMed 3071950]  Request Paper

1987

13. Bruchovsky N, Brown EM, Coppin CM, Goldenberg SL, Le Riche JC, Murray NC, Rennie PS. The endocrinology and treatment of prostate tumor progression. Prog Clin Biol Res 239:347-87. (1987).
     [View Abstract - PubMed 3309961]  Request Paper

1978

14. Bruchovsky N, Rennie PS, Doorn EV, Noble RL. Pathological growth of androgensensitive tissues resulting from latent actions of steroid hormones. J Toxicol Environ Health 4(2-3):391-408. (1978).
     [View Abstract - PubMed 351203]  Request Paper

1976

15. Bruchovsky N, Lesser B. Control of proliferative growth in androgen responsive organs and neoplasms. Adv Sex Horm Res 2:1-55. (1976).
     [View Abstract - PubMed 65115]  Request Paper

1975

16. Bruchovsky N, Lesser B, Van Doorn E, Craven S. Hormonal effects on cell proliferation in rat prostate. Vitam Horm 33:61-102. (1975).
     [View Abstract - PubMed 180681]  Request Paper

In Press

1. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x_c- cystine transporter: A new action for an old drug. Leukemia (In Press).
    Request Paper

2. Tilley WD, Clarke CL, Birrell SN, Bruchovsky N. Hormones and cancer: new insights, new challenges. Trends Endocrinol Metab (In Press).
    Request Paper

2001

3. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by IL-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem, (accepted for publication) (2001).
    Request Paper

2000

4. Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 56(2):289-94. (2000).
    [View Abstract - PubMed 10925096]  Request Paper

1999

5. Bruchovsky N, Wilson JD. Discovery of the role of dihydrotestosterone in androgen action. Steroids 64(11):753-9. (1999).
    [View Abstract - PubMed 10577831]  Request Paper

6. Goldenberg SL, Gleave ME, Bruchovsky N. The role of intermittent androgen suppression in prostate cancer. Amer Urol Assoc Update Ser 17:18-23. (1999).
    Request Paper

7. Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N. Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up. Mol Urol 3(3):287-292. (1999).
    [View Abstract - PubMed 10851335]  Request Paper

8. Kasper S, Rennie PS, Bruchovsky N, Lin L, Cheng H, Snoek R, Dahlman-Wright K, Gustafsson JA, Shiu RP, Sheppard PC, Matusik RJ. Selective activation of the probasin androgen-responsive region by steroid hormones. J Mol Endocrinol 22(3):313-25. (1999).
    [View Abstract - PubMed 10343290]  Request Paper

9. Nelson CC, Hendy SC, Shukin RJ, Cheng H, Bruchovsky N, Koop BF, Rennie PS. Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: evidence for differential steroid receptor response elements. Mol Endocrinol 13(12):2090-107. (1999).
    [View Abstract - PubMed 10598584]  Request Paper

1998

10. Gleave ME, Goldenberg SL, Bruchovsky N, Rennie PS. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer and Prostatic Diseases 1:289-296. (1998).
     Request Paper

11. Gleave ME, Goldenberg SL, Jones ED, Bruchovsky N, Sullivan LD. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: analysis of outcome by pre-operative risk factors. Mol Urol 2:171-177. (1998).
     Request Paper

12. Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. J Cell Biochem 69(3):271-81. (1998).
     [View Abstract - PubMed 9581866]  Request Paper

13. Snoek R, Bruchovsky N, Kasper S, Matusik RJ, Gleave M, Sato N, Mawji NR, Rennie PS. Differential transactivation by the androgen receptor in prostate cancer cells. Prostate 36(4):256-63. (1998).
     [View Abstract - PubMed 9719026]  Request Paper

1997

14. Bruchovsky N, Goldenberg SL, Gleave ME. Intermittent hormonal therapy for prostate cancer. Adv Urol 10:291-326. (1997).
     Request Paper

15. Bruchovsky N, Goldenberg SL, Gleave ME, Rennie PS, Akakura K, Sato N. Intermittent therapy for prostate cancer. Endocrine-Related Cancer 4:153-177. (1997).
     Request Paper

16. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy in clinically confined prostate cancer: biochemical and pathological effects. Mol Urol 1:199-205. (1997).
     Request Paper

17. Gleave ME, Sato N, Goldenberg SL, Stothers L, Bruchovsky N, Sullivan LD. Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model. J Urol 157(5):1727-30. (1997).
     [View Abstract - PubMed 9112514]  Request Paper

18. Goldenberg SL, Gleave ME, Bruchovsky N. Mechanisms of androgen-independent tumor growth. Can J Urol 4(2):Suppl:65-67. (1997).
     Request Paper

19. Gout PW, Kang YJ, Buckley DJ, Bruchovsky N, Buckley AR. Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells. Leukemia 11(8):1329-37. (1997).
     [View Abstract - PubMed 9264389]  Request Paper

20. Hall R, Hedlund PO, Ackermann R, Bruchovsky N, Dalesio O, Debruyne F, Murphy GP, Parmar MK, Pavone-Macaluso M, Ruutu M, Smith P. Evaluation and follow-up of patients with N1-3 M0 or NXM1 prostate cancer in phase III trials. Urology 49(4A Suppl):39-45. (1997).
     [View Abstract - PubMed 9111613]  Request Paper

21. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res 57(8):1584-9. (1997).
     [View Abstract - PubMed 9108464]  Request Paper

22. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem 272(28):17485-94. (1997).
     [View Abstract - PubMed 9211894]  Request Paper

1996

23. Akakura K, Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, Tenniswood M, Fox K. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma. J Steroid Biochem Mol Biol 59(5-6):501-11. (1996).
     [View Abstract - PubMed 9010356]  Request Paper

24. Bruchovsky N, Sadar MD, Akakura K, Goldenberg SL, Matsuoka K, Rennie PS. Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol 59(5-6):397-404. (1996).
     [View Abstract - PubMed 9010345]  Request Paper

25. Gleave M, Santo N, Rennie PS, Goldenberg SL, Bruchovsky N, Sullivan LD. Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer. Prog Urol 6(3):375-85. (1996).
     [View Abstract - PubMed 8763692]  Request Paper

26. Gleave ME, Bruchovsky N, Goldenberg SL, Sato N, Rennie PS. Intermittent androgen suppression. Urol Int 3:8-10. (1996).
     Request Paper

27. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155(1):213-9. (1996).
     [View Abstract - PubMed 7490838]  Request Paper

28. Goldenberg SL, Bruchovsky N, Gleave ME. The role of intermittent androgen blockade in prostate cancer. Horm Ther Androl Urol 1:21-25 (1996).
     Request Paper

29. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD. Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration. Urology 47(6):882-4. (1996).
     [View Abstract - PubMed 8677581]  Request Paper

30. Kaefer M, Audia JE, Bruchovsky N, Goode RL, Hsiao KC, Leibovitch IY, Krushinski JH, Lee C, Steidle CP, Sutkowski DM, Neubauer BL. Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells. J Steroid Biochem Mol Biol 58(2):195-205. (1996).
     [View Abstract - PubMed 8809201]  Request Paper

31. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 58(2):139-46. (1996).
     [View Abstract - PubMed 8809195]  Request Paper

32. Snoek R, Rennie PS, Kasper S, Matusik RJ, Bruchovsky N. Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides. J Steroid Biochem Mol Biol 59(3-4):243-50. (1996).
     [View Abstract - PubMed 9010316]  Request Paper

1994

33. Bruchovsky N. The rationale for intermittent androgen-suppression therapy in prostate cancer. Prospectives 4(6):6-8 (1994).
     Request Paper

34. Dedhar S, Rennie PS, Shago M, Hagesteijn CY, Yang H, Filmus J, Hawley RG, Bruchovsky N, Cheng H, Matusik RJ, et al. Inhibition of nuclear hormone receptor activity by calreticulin. Nature 367(6462):480-3. (1994).
     [View Abstract - PubMed 8107809]  Request Paper

35. Gout PW, Horsman DE, Fox K, De Jong G, Ma S, Bruchovsky N. The rat Nb2 lymphoma: a novel model for tumor progression. Anticancer Res 14(6B):2485-92. (1994).
     [View Abstract - PubMed 7872671]  Request Paper

36. Kasper S, Rennie PS, Bruchovsky N, Sheppard PC, Cheng H, Lin L, Shiu RP, Snoek R, Matusik RJ. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J Biol Chem 269(50):31763-9. (1994).
     [View Abstract - PubMed 7989349]  Request Paper

37. Rennie PS, Bruchovsky N, Akakura K, Goldenberg SL, Otal N, Akakura S, Wong P, Tenniswood M. Effect of tumour progression on the androgenic regulation of the androgen receptor, TRPM-2 and YPT1 genes in the Shionogi carcinoma. J Steroid Biochem Mol Biol 50(1-2):31-40. (1994).
     [View Abstract - PubMed 8049130]  Request Paper

1993

38. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71(9):2782-90. (1993).
     [View Abstract - PubMed 7682149]  Request Paper

39. Bruchovsky N, Goldenberg SL, Akakura K, Rennie PS. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer 72(5):1685-91. (1993).
     [View Abstract - PubMed 7688656]  Request Paper

40. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS, et al.. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 7(1):23-36. (1993).
     [View Abstract - PubMed 8446105]  Request Paper

41. Rennie PS, Mawji NR, Coldman AJ, Godolphin W, Jones EC, Vielkind JR, Bruchovsky N. Relationship between variant forms of estrogen receptor RNA and an apoptosis-related RNA, TRPM-2, with survival in patients with breast cancer. Cancer 72(12):3648-54. (1993).
     [View Abstract - PubMed 8252481]  Request Paper

1990

42. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50(8):2275-82. (1990).
     [View Abstract - PubMed 2317815]  Request Paper

43. Jones EC, McNeal J, Bruchovsky N, de Jong G. DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage Gleason grade 4 and 5, and lymph node metastases. Cancer 66(4):752-7. (1990).
     [View Abstract - PubMed 2386903]  Request Paper

44. Rennie PS, Bruchovsky N, Coldman AJ. Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J Steroid Biochem Mol Biol 37(6):843-7. (1990).
     [View Abstract - PubMed 2126735]  Request Paper

1989

45. Ho KC, Snoek R, Quarmby V, Viskochil DH, Rennie PS, Wilson EM, French FS, Bruchovsky N. Primary structure and androgen regulation of a 20-kilodalton protein specific to rat ventral prostate. Biochemistry 28(15):6367-73. (1989).
     [View Abstract - PubMed 2477055]  Request Paper

46. Petrow V, Padilla GM, McPhail AT, Bruchovsky N, Schneider SL. Prostate. III--A structural feature characteristic of the rat prostate 5 alpha-reductase active site. J Steroid Biochem 32(3):399-407. (1989).
     [View Abstract - PubMed 2704237]  Request Paper

47. Rennie PS, Bowden JF, Freeman SN, Bruchovsky N, Cheng H, Lubahn DB, Wilson EM, French FS, Main L. Cortisol alters gene expression during involution of the rat ventral prostate. Mol Endocrinol 3(4):703-8. (1989).
     [View Abstract - PubMed 2498651]  Request Paper

1988

48. Bruchovsky N, Rennie PS, Batzold FH, Goldenberg SL, Fletcher T, McLoughlin MG. Kinetic parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates. J Clin Endocrinol Metab 67(4):806-16. (1988).
     [View Abstract - PubMed 2458378]  Request Paper

49. Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CM. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. J Urol 140(6):1460-5. (1988).
     [View Abstract - PubMed 2973529]  Request Paper

50. Rennie PS, Bowden JF, Bruchovsky N, Cheng H. The relationship between inhibition of plasminogen-activator activity and prostatic involution. Biochem J 252(3):759-64. (1988).
     [View Abstract - PubMed 2458715]